GlucoTrack (GCTK) 10-K 31 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 27, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Entity Registrant Name	Integrity Applications, Inc.
Entity Central Index Key	1,506,983
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,047,640
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 18,598,536

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 148,836	$ 608,701
Accounts receivable, net	92,061	18,446
Inventories (Note 3)	1,419,604	816,223
Other current assets (Note 4)	356,994	268,792
Total current assets	2,017,495	1,712,162
Property and Equipment, Net (Note 5)	240,452	220,463
Long-Term Restricted Cash	35,673	35,152
Funds in Respect of Employee Rights Upon Retirement	167,326	164,883
Total assets	2,460,946	2,132,660
Current Liabilities
Accounts payable	1,634,642	1,082,546
Other current liabilities (Note 6)	713,549	427,886
Total current liabilities	2,348,191	1,510,432
Long-Term Liabilities
Long-Term Loans from Stockholders (Note 8)	162,034	160,314
Liability for Employee Rights Upon Retirement (Note 2J)	176,719	174,137
Warrants with Down-Round Protection (Note 10E)	681,970	321,695
Total long-term liabilities	1,020,723	656,146
Total liabilities	3,368,914	2,166,578
Commitments and Contingent Liabilities (Note 9)
Temporary Equity (Note 10.A)
Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock"):
Total Temporary Equity	10,041,462	6,936,996
Stockholders' Deficit
Common Stock of $ 0.001 par value ("Common Stock"): 40,000,000 shares authorized as of December 31, 2016, and December 31, 2015; issued and outstanding 6,026,527 shares and 5,690,097 shares as of December 31, 2016, and December 31, 2015, respectively	6,028	5,691
Additional paid in capital	24,586,142	22,309,742
Accumulated other comprehensive income	62,576	90,168
Accumulated deficit	(35,604,176)	(29,376,515)
Total stockholders' deficit	(10,949,430)	(6,970,914)
Total liabilities, temporary equity and stockholders' deficit	2,460,946	2,132,660
Series A Preferred Stock [Member]
Temporary Equity (Note 10.A)
Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock"):	221,152	221,152
Series B Preferred Stock [Member]
Temporary Equity (Note 10.A)
Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock"):	6,715,844	6,715,844
Series C Preferred Stock [Member]
Temporary Equity (Note 10.A)
Convertible Preferred Stock of $ 0.001 par value ("Preferred Stock"):	$ 3,104,466

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Temporary Equity
Common Stock, par value per share	$ 0.001	$ 0.001
Common Stock, shares authorized	40,000,000	40,000,000
Common Stock, shares issued	6,026,527	5,690,097
Common Stock, shares outstanding	6,026,527	5,690,097
Preferred Stock [Member]
Temporary Equity
Convertible Preferred Stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred Stock, shares authorized	10,000,000	10,000,000
Series A Preferred Stock [Member]
Temporary Equity
Convertible Preferred Stock, shares issued	376	376
Convertible Preferred Stock, shares outstanding	376	376
Series B Preferred Stock [Member]
Temporary Equity
Convertible Preferred Stock, shares issued	15,031	15,031
Convertible Preferred Stock, shares outstanding	15,031	15,031
Series C Preferred Stock [Member]
Temporary Equity
Convertible Preferred Stock, par value per share	$ 0.001	$ 0.001
Convertible Preferred Stock, shares issued	5,829	0
Convertible Preferred Stock, shares outstanding	5,829	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues		$ 611,689	$ 143,167	$ 59,775
Research and development expenses (Note 11)		2,881,817	2,268,345	1,849,624
Selling and Marketing expenses (Note 12)		1,127,915	1,127,434	230,759
General and administrative expenses (Note 13)		2,257,799	1,402,741	1,586,751
Total operating expenses		6,267,531	4,798,520	3,667,134
Operating loss		5,655,842	4,655,353	3,607,359
Financing (income) expenses, net (Note 14)		(246,105)	1,186,819	(6,587,785)
Income (loss) for the period		(5,409,737)	(5,842,172)	2,980,426
Other comprehensive income (loss):
Foreign currency translation adjustment		(27,592)	23,498	13,968
Comprehensive income (loss) for the period		$ (5,437,329)	$ (5,818,674)	$ 2,994,394
Income (loss) per share (Basic) (Note 16)		$ (1.08)	$ (1.15)	$ 0.37
Income (loss) per share (Diluted) (Note 16)		$ (1.08)	$ (1.15)	$ 0.37
Common shares used in computing Basic income (loss) per share (Note 16)		5,788,842	5,476,870	5,304,500
Common shares used in computing Diluted income (loss) per share (Note 16)	[1]	5,788,842	5,476,870	5,349,242
[1]	In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C).

STATEMENTS OF CHANGES IN STOCKH

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Additional paid in capital [Member]	Accumulated other comprehensive income [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2013	$ 5,302	$ 14,532,068	$ 52,702	$ (25,653,190)	$ (11,063,118)
Balance, shares at Dec. 31, 2013	5,301,693
Income (loss) for the year				2,980,426	2,980,426
Other comprehensive income (loss)			13,968
Amounts allocated to Series B-1 and Series B-2 Warrants, net		3,320,429
Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities		(400,671)			(400,671)
Conversion of Preferred Stock	$ 2	5,886
Conversion of Preferred Stock, shares	1,725
Warrants issued as consideration for placement services		630,936
Stock dividend to certain Common Stock holders	$ 1	(1)
Stock dividend to certain Common Stock holders, shares	654
Stock dividend on Series B Preferred Stock	$ 19	43,839		(43,858)
Stock dividend on Series B Preferred Stock, shares	18,986
Cash dividend on Series A Preferred Stock				(370,441)
Stock-based compensation		50,380
Balance at Dec. 31, 2014	$ 5,324	18,182,866	66,670	(23,087,063)	$ (4,832,203)
Balance, shares at Dec. 31, 2014	5,323,058				5,323,058
Income (loss) for the year				(5,842,172)	$ (5,842,172)
Other comprehensive income (loss)			23,498		23,498
Issuance of Series B-1 and Series B-2 Warrants		3,445,337			3,445,337
Conversion of Preferred Stock	$ 86	237,451			237,537
Conversion of Preferred Stock, shares	86,208
Stock dividend to certain Common Stock holders	$ 92	(92)
Stock dividend to certain Common Stock holders, shares	92,136
Stock dividend on Series B Preferred Stock	$ 169	390,050		(390,219)
Stock dividend on Series B Preferred Stock, shares	168,926
Cash dividend on Series A Preferred Stock				(57,061)	(57,061)
Exercise of employees' stock options	$ 20	36,117			36,137
Exercise of employees' stock options, shares	19,769
Stock-based compensation		18,013			18,013
Balance at Dec. 31, 2015	$ 5,691	22,309,742	90,168	(29,376,515)	$ (6,970,914)
Balance, shares at Dec. 31, 2015	5,690,097				5,690,097
Income (loss) for the year				(5,409,737)	$ (5,409,737)
Other comprehensive income (loss)			(27,592)		(27,592)
Amounts allocated to Series C-1 and Series C-2 Warrants, net		1,537,380			1,537,380
Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities		(341,662)			(341,662)
Incremental fair market value adjustments of modified warrants issued to placement agent		211,077			211,077
Stock dividend on Series C Preferred Stock	$ 65	152,415		(152,480)
Stock dividend on Series C Preferred Stock, shares	64,148
Stock dividend on Series B Preferred Stock	$ 272	646,943		(647,215)
Stock dividend on Series B Preferred Stock, shares	272,282
Cash dividend on Series A Preferred Stock				(18,229)	(18,229)
Stock-based compensation		70,247			70,247
Balance at Dec. 31, 2016	$ 6,028	$ 24,586,142	$ 62,576	$ (35,604,176)	$ (10,949,430)
Balance, shares at Dec. 31, 2016	6,026,527				6,026,527

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Income (loss) for the year	$ (5,409,737)	$ (5,842,172)	$ 2,980,426
Adjustments to reconcile income (loss) for the year to net cash used in operating activities:
Depreciation	59,584	44,891	34,683
Stock-based compensation	70,247	18,013	50,380
Incremental fair market value adjustments of modified warrants issued to placement agent	211,077
Change in the fair value of warrants issued with down-round protection	(289,626)	(149,092)	(6,559,758)
Linkage difference on principal of loans from stockholders	(629)	(2,521)	(556)
Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants		1,284,354
Changes in assets and liabilities:
Decrease (increase) in accounts receivable	(73,440)	4,131	(24,539)
Increase in inventory	(590,616)	(737,554)	(94,895)
Increase in other current assets	(85,415)	(156,302)	(32,416)
Increase in accounts payable	526,560	982,215	68,838
Increase (decrease) in other current liabilities	270,165	(11,187)	216,192
Net cash used in operating activities	(5,311,830)	(4,565,224)	(3,361,645)
Cash flows from investment activities:
Increase in funds in respect of employee rights upon retirement		(24,279)	(28,058)
Purchase of property and equipment	(76,455)	(143,736)	(63,455)
Increase in long-term restricted cash		(35,152)
Net cash used in investment activities	(76,455)	(203,167)	(91,513)
Cash flows from financing activities
Cash dividend on Series A Preferred Stock	(13,529)	(57,061)	(370,441)
Proceeds allocated to Series B Preferred Stock, net of cash issuance expenses			3,710,860
Proceeds allocated to Series B Warrants, net of cash issuance expenses			3,632,531
Proceeds allocated to Series C Preferred Stock, net of cash issuance expenses	3,310,617
Proceeds allocated to Series C Warrants, net of cash issuance expenses	1,639,468
Proceeds from exercise of employees’ stock options		36,137
Repayment of loan from stockholders		(439,939)
Net cash provided by (used in) financing activities	4,936,556	(460,863)	6,972,950
Effect of exchange rate changes on cash and cash equivalents	(8,136)	10,395	(78,143)
Increase (decrease) in cash and cash equivalents	(459,865)	(5,218,859)	3,441,649
Cash and cash equivalents at beginning of the year	608,701	5,827,560	2,385,911
Cash and cash equivalents at end of the year	$ 148,836	$ 608,701	$ 5,827,560

CONSOLIDATED STATEMENTS OF CAS7

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Conversion of Stock [Line Items]
Non-cash charge recorded to finance expense as result of warrant exchange		$ 1,284,354
Warrants issued as consideration for placement agent services	$ 308,239
Amount of direct issuance expense allocated to Series C-1 and Series C-2 Warrants and recorded as a reduction of additional paid in capital	102,088
Amount of direct issuance expense allocated to Series C Preferred Stock and recorded as a reduction of temporary equity	206,151
Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities	341,662
Series B-1 Warrant [Member]
Conversion of Stock [Line Items]
Number of warrants exchanged		1,200,710
Increase (decrease) in equity due to exchange of warrants		$ 1,833,876
Series B-2 Warrant [Member]
Conversion of Stock [Line Items]
Number of warrants exchanged		1,200,710
Increase (decrease) in equity due to exchange of warrants		$ 1,612,186
Warrant [Member]
Conversion of Stock [Line Items]
Number of warrants exchanged		1,440,880
Increase (decrease) in equity due to exchange of warrants		$ (1,586,831)
Series B and C Preferred Stock [Member]
Conversion of Stock [Line Items]
Stock dividend	$ 799,695
Interest rate	9.00%
Series A Preferred Stock [Member]
Conversion of Stock [Line Items]
Number of preferred shares converted	23.2
Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares		6,931
Increase (decrease) in equity due to exchange of warrants		$ (4,076,688)
Cash dividend	$ 4,700
Series A Preferred Stock [Member] | Conversion of Preferred Stock Into Common Stock [Member]
Conversion of Stock [Line Items]
Number of preferred shares converted		100
Stock issued upon conversion		17,242
Amount of stock converted		$ 58,817
Series B Preferred Stock [Member]
Conversion of Stock [Line Items]
Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares		6,931
Increase (decrease) in equity due to exchange of warrants		$ 3,502,536
Stock dividend	647,215	$ 390,219
Series B Preferred Stock [Member] | Conversion of Preferred Stock Into Common Stock [Member]
Conversion of Stock [Line Items]
Number of preferred shares converted		400
Stock issued upon conversion		68,966
Amount of stock converted		$ 178,720
Series C Preferred Stock [Member]
Conversion of Stock [Line Items]
Stock dividend	$ 152,480

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 - GENERAL A. Integrity Applications, Inc. (the "Company") was incorporated on May 18, 2010 under the laws of the State of Delaware. On July 15, 2010, Integrity Acquisition Corp. Ltd. (hereinafter: "Integrity Acquisition"), a wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: "Integrity Israel"), an Israeli corporation that was previously held by the stockholders of the Company. Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel remained a wholly-owned subsidiary of the Company. As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002. Integrity Israel, a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. B. Going concern uncertainty and management plans Since its incorporation, the Company did not conduct any material operations other than those carried out by Integrity Israel. The development and commercialization of Integrity Israel's product is expected to require substantial expenditures. Integrity Israel and the Company (collectively, the "Group") have not yet generated significant revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of December 31, 2016, the Group has incurred accumulated deficit of $35,604,176, stockholder's deficit of $10,949,430 and negative operating cash flows. Management considered the significance of such conditions in relation to the group’s ability to meet its current and future obligations and determined that these conditions raise substantial doubt about the Group’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. During the period between August and December of 2014, the Company raised funds in an aggregate amount of approximately $7.3 million (net of related cash expenses) from the issuance of units (the “Series B Units”), each consisting of (a) one share of the Company’s designated Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), convertible into Common Stock at an initial conversion price of $5.80 per share, (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a “Series B-1 Warrant”) and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred Stock (each a “Series B-2 Warrant” and, together with the Series B-1 Warrants, collectively, the “Series B Warrants”), During the year ended December 31, 2016, the Company raised funds in an aggregate amount of approximately $4.95 million (net of related cash expenses) through the issuance of 5,829 units (the “Series C Units”), each consisting of (a) one share of the Company’s newly designated Series C 5.5% Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), convertible into Common Stock at an initial conversion price of $4.50 per share, (b) a five year warrant to purchase, at an exercise price of $4.50 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-1 Warrant”) and (c) a five year warrant to purchase, at an exercise price of $7.75 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-2 Warrant” and, together with the Series C-1 Warrants, collectively, the “Series C Warrants”),see Also Note 10A.4 and Note 10D. Until such time as the Group generates sufficient revenue to fund its operations (if ever), the Group plans to finance its operations through the sale of equity or equity-linked securities and/or debt securities and, to the extent available, short term and long term loans. There can be no assurance that the Group will succeed in obtaining the necessary financing to continue its operations as a going concern. C. Risk factors As described in Note 1A and Note 1B above, the Group has a limited operating history and faces a number of risks and uncertainties, including risks and uncertainties regarding continuation of the development process, demand and market acceptance of the Group's products, the effects of technological changes, competition and the development of products by competitors. Additionally, other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group's future results and the availability of necessary financing. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development of its products and marketing efforts. The Group has not yet generated material revenues from its operations to fund its activities and therefore is dependent on the receipt of additional funding from its stockholders and/ or new investors in order to continue its operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). A. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the B. Functional currency The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' deficit, under “accumulated other comprehensive income (loss)”. Year ended December 31, 2016 2015 2014 Official exchange rate of NIS 1 to US dollar 0.260 0.256 0.257 C. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation. D. Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents. E. Inventories Inventories are stated at the lower of cost or market value. Cost is determined as follows: With respect to raw materials, the Group calculates cost using the average cost method. With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs. Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory. F. Property and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: % Computers 33 Furniture and office equipment 7-15 Leasehold improvements Shorter of lease term G. Impairment of long-lived assets The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses. H. Long-term restricted cash Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel’s obligations in respect of its headquarters lease. See Note 9B I. Income tax The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2016, 2015 and 2014 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet. J. Liability for employee rights upon retirement Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds. The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses. Commencing in 2011, Integrity Israel’s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet. Severance expenses for the year ended December 31, 2016, 2015 and 2014 amounted to $147,754, $111,030 and $101,220, respectively. K. Revenue recognition Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (“SAB”) No. 104, “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N). The Company derives its revenues from sales of its GlucoTrack® model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes. L. Research and development expenses Research and development expenses are charged to operations as incurred. M. Royalty-bearing grants Royalty-bearing grants from the Office of Chief Scientist (“OCS”) to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300. Integrity Israel has not received any research and development grants since December 2004. N. Warranty The Group provides a 24-month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended December 31, 2016, 2015 and 2014 warranty expenses were $8,605 and, $1,157 and $0, respectively. O. Basic and diluted income (loss) per share Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two-class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company. In computing, diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method” and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive. P. Stock-based compensation The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees". Q. Fair value of financial instruments ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short-term maturities of such financial instruments. The Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy. The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined. R. Concentrations of credit risk Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2016, and 2015 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. S. Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. T. Preferred Stock 1. Temporary Equity Classification As more fully described in Note 10 the Company issued Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company’s control. Accordingly, the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock are presented as temporary equity. 2. Initial Measurement Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series C Preferred Stock issued together with detachable Series C Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them. 3. Subsequent Measurement On each balance sheet date, the Company’s management assesses the probability of redemption of the Preferred Stock (Series A, B or C). In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date. 4. Conversion Feature Analysis The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A, Series B and Series C Preferred Stock, are considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock, the effective exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock into Common Stock) was higher than the estimated fair value of the Company’s Common Stock, it was determined that the conversion feature was not beneficial. 5. Modifications or Exchanges Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification. U. Series A Warrants with Down-Round Protection The Company considered the provisions of ASC 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity”, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers and to the placement agent, as described in Note 10D, and determined that as a result of the “down-round” protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred. V. Recently Issued Accounting Pronouncements 1. Accounting Standard Update 2014-09, “Revenue from Contracts with Customers” In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. During 2016, the FASB issued several Accounting Standard Updates (“ASUs”) that focus on certain implementation issues of the new revenue recognition guidance including Narrow-Scope Improvements, Practical Expedients and technical corrections. In accordance with an amendment to ASU 2014-09, introduced by Accounting Standard 2015-14, “Revenue from contracts with Customers – Deferral of the Effective Date”, for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company intends to adopt ASU 2014-09 as of January 1, 2018. The Company is in the process of evaluation the impact of ASU 2014-09 on its revenue streams and selling contracts, if any, and on its financial reporting and disclosures. Management is expecting to complete the evaluation of the impact of the accounting and disclosure changes on the business processes, controls and systems throughout 2017. Since the company did not report significant revenues, management believes that the adoption of ASU 2014-09 will not have significant impact on its financial statements. 2. Accounting Standards Update 2014-15, “Presentation of Financial Statements—Going Concern” In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management’s evaluation. The amendments in ASU 2014-15 became effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Due to the current financial condition of the Company and the existing uncertainty regarding its ability to continue as a going concern, the provisions of ASU 2014-15 did not have a significant effect on the management evaluation of the Company’s ability to continue as a going concern. Certain disclosures were updated to conform to the disclosures required under ASU 2014-15. 3. Accounting Standard Update 2014-16, “Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity” Effective January 1, 2016, the Group adopted Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16"). The amendments in ASU 2014-16 clarify how U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes. The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of shares. The effects of initially adopting the amendments in ASU 2014-16 were required to be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of shares as of the beginning of the fiscal year for which the amendments are effective. However, retrospective application was permitted to all relevant prior periods. Management analyzed the economic characteristics and risks of the Series A Preferred Stock and the Series B Preferred Stock (including the embedded conversion feature of each) in accordance with the provisions of ASU 2014-16 and determined that such instruments are considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related and accordingly, the embedded conversion feature was not required to be bifurcated. As a result of the above determination, ASU 2014-16 did not impact the classification of the Series A Preferred Stock or the Series B Preferred Stock. 4. Accounting Standard Update 2015-11, “Simplifying the Measurement of Inventory” In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period. Management does not believe that the adoption of ASU 2015-11 will have significant effect on the consolidated financial statements. W. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s deficit or cash flows .

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 3 – INVENTORIES US dollars December 31, 2016 2015 Raw materials 735,201 205,645 Work in process 633,132 551,111 Finished products 51,271 59,467 1,419,604 816,223

OTHER CURRENT ASSETS

OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2016
Other Assets [Abstract]
OTHER CURRENT ASSETS	NOTE 4 – OTHER CURRENT ASSETS US dollars December 31, 2016 2015 Prepaid expenses 90,563 57,206 Government Institution (*) 266,431 211,586 356,994 268,792 (*) Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5 – US dollars December 31, 2016 2015 Computers 274,693 240,066 Furniture and office equipment 237,240 200,548 Leasehold improvements 44,686 32,898 556,619 473,512 Less – accumulated depreciation (316,167 ) (253,049 ) 240,452 220,463 During the years ended December 31, 2016, 2015 and 2014, depreciation expenses amounted to $59,584, $44,891 and $34,683, respectively, and new equipment purchases amounted to $76,455, $143,736 and $63,455, respectively.

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
OTHER CURRENT LIABILITIES	NOTE 6 – US dollars December 31, 2016 2015 Employees and related institutions 363,738 240,358 Accrued expenses and other 349,811 187,528 713,549 427,886

LINE OF CREDIT

LINE OF CREDIT	12 Months Ended
	Dec. 31, 2016
Line of Credit Facility [Abstract]
LINE OF CREDIT	NOTE 7 – As of December 31, 2016, the Group had an unutilized credit line of approximately $38,500 (NIS 150,000) with its Israeli bank. Borrowings under the line of credit are secured by funds on deposit with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in full.

LONG-TERM LOANS FROM STOCKHOLDE

LONG-TERM LOANS FROM STOCKHOLDERS	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
LONG-TERM LOANS FROM STOCKHOLDERS	NOTE 8 – LONG-TERM LOANS FROM STOCKHOLDERS During the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders). The loans are indexed to the Israeli Consumer Price Index from their origination date and bear no interest. The Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year in which the Group reports net profit in its annual report. At such time, the Group will be required to make quarterly payments equal to 10% of its total sales for each quarter until the loans have been repaid in full. Notwithstanding the repayment mechanism, the Group will not be required to repay the loans during any period in which such payment would cause a deficit in the Group's working capital. From June of 2011 Integrity Israel, Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman, on the one hand, and Dimri, on the other hand, which was a shareholder of Integrity Israel prior to the reorganization and merger (See Note 1A above), were involved in arbitration proceedings resulting from certain claims asserted by Dimri following such reorganization. Pursuant to the terms of the Arbitration Decision, (1) Avner Gal, David Malka, Zvi Cohen, Ilana Freger and Alexander Raykhman transferred to Dimri, on March 18, 2015, an aggregate of 440,652 shares of the Company’s outstanding Common Stock held collectively by such shareholders, (2) Integrity Israel (A) paid to Dimri on March 23, 2015, NIS 1,767,674 or $439,939 (based on the exchange rate of 4.018 NIS:$1 as of March 23, 2015), as repayment in full of the outstanding principal amount under Dimri’s investment agreement with Integrity Israel and the founders (the “Investment Agreement”), as adjusted for changes in the Israeli consumer price index since the date on which the loan was made, and (B) paid to Dimri on April 30, 2015, NIS 316,100 or $81,870 (based on the exchange rate of 3.861 NIS:$1 as of April 30, 2015), as partial reimbursement of Dimri’s attorney’s fees in the arbitration. The Company accrued for the fee reimbursement obligation as part of professional fees within selling, marketing and general and administrative expenses included in its results of operations for the fiscal year ended December 31, 2014. During March 2015, such amount was fully paid. As of December 31, 2016, the Group does not expect to make any additional material repayments during the following 12-month period, if any, and accordingly the entire balance of the loans from stockholders have been presented as long-term liabilities.

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 9 – A. On March 4, 2004, the OCS provided Integrity Israel with a grant of approximately $93,300 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the “Development Plan”). Integrity Israel is required to pay royalties to the OCS at a rate ranging between 3-5% of the proceeds from the sale of the Group's products arising from the Development Plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December 31, 2016, the remaining contingent liability with respect to royalty payment on future sales equals approximately $69,330, excluding interest. Such contingent obligation has no expiration date. As of December 31, 2016, 2015 and 2014, the Group accrued royalties to the OCS in the amounts of $14,011, $8,167 and $1,793, respectively B. Until mid of December 2015, Integrity Israel leased approximately 3,100 sq. ft. of office space in the city of Ashkelon, Israel as its principal offices and prototype laboratory. Pursuant to a verbal agreement with the landlord, Integrity Israel leased this facility on a monthly basis at a cost of approximately $2,934 (NIS 11,500). Currently, Integrity Israel leases approximately 5,500 sq. ft. of office space in the city of Ashdod, Israel for its principal offices. The lease term began on December 1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company. Monthly lease payments including maintenance approximate $10,000. The Company estimates that its minimal rent and maintenance payments will approximate $120,000 per year over each of the next 5 years. In connection with the lease agreement, Integrity Israel provided the landlord a bank guarantee in the amount of approximately $35,000 (NIS 137,162) that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent payments. The guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank, which generally must be sufficient to cover the principal amount guarantee. C. During 2014, the Company engaged the Placement Agent in connection with an offering of up $25,000,000 of its securities, which engagement ultimately culminated in the issuance and sale of $8,500,000 Series B Units (the “2014 Offering”). Pursuant to a placement agent agreement with the Placement Agent entered into with respect to such private placement, the Placement Agent (or its sub-agents) was paid, as a commission, an amount equal to 6% of the funds raised in each, such offering, plus 4% of the funds as a management fee plus a 3% non-accountable expense allowance (13% in the aggregate), all in cash. In addition, pursuant to such placement agent agreement, the Company was required to and did issue to the Placement Agent (or its sub-agents) warrants to purchase up to 10% of the shares of Common Stock issued to investors (or underlying convertible securities issued to investors) in connection with such offerings at a price per share equal to the offering price subject to certain price adjustments. Based on the agreement signed in 2014, the Placement Agent will have a right of first refusal on any private equity, debt or rights offering for a period of 24 months from the date on which marketing efforts with respect to the 2014 offering began. In addition, pursuant to such agreement, the Company was required to use its reasonable efforts to have the Placement Agent named as a co-underwriter in any secondary public offering by the Company in the 12 months following completion of the 2014 offering. In addition, starting in September 2013, the Company retained the Placement Agent to provide certain advisory services for a monthly fee of $12,500 for the period starting September 2013 until December 2014 and $20,000 per month starting from January 2015. During February 2016, the Company entered into an Advisory Agreement with the placement agent (“AGI’), pursuant to which the Company retained AGI on a non-exclusive basis to provide certain advisory services to the Company. As consideration for such services, the Company extended through December 31, 2019, the expiration date of 364,071 warrants issued to AGI and/or its designees in connection with the Company’s common stock offering completed in 2010 and the Series A Unit offering completed in 2012. The Advisory Agreement had an initial term of six months, subject to automatic renewal for additional 30 day terms unless terminated by either party with 30 days written notice. In April 2016, the Company and AGI amended again that Advisory Agreement to extend the term of the Advisory Agreement for an additional six months until March of 2017 and is not expected to be renewed. In consideration for such extension, the Company agreed to modify the terms of the 439,674 warrants issued to AGI and/or its designees in connection with the Series B unit offering to include full-ratchet anti-dilution protection. As a result of the two agreements the company recorded in its statement of operations for the year ended December 31, 2016, a one-time charge in the amount of $211,077 representing the incremental fair market value adjustments in respect of the above modified warrants issued to the placement agent. Such incremental fair market value adjustments represent the increase in the fair value of the warrants resulting from the above modifications and were recorded against stockholders’ deficit. In addition, as a result of the inclusion of anti-dilution protection, the Company classified $341,662, representing the fair market value at March 2016 of the above 439,674 warrants issued to AGI (after the above modification) out of stockholders’ deficit and presented them as Warrants with down round protection within long-term liabilities . The Company paid the Placement Agent $1,014,974, $185,000 and $1,255,606, in cash during 2016, 2015, and 2014, respectively in connection with the above advisory service agreements and the offerings. See Notes 10B, Note 10D and Note 10F.1 with respect to warrants issued to the Placement Agent.

COMMON STOCK, PREFERRED STOCK A

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION	12 Months Ended
	Dec. 31, 2016
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT
COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION	NOTE 10 – A. 1 Description of the rights attached to the Common Stock Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company’s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. As described below, holders of Preferred Stock are entitled to vote together with the holders of Common Stock on an as-converted basis. Accordingly, the holders of the Company's Common Stock together with the holders of the Preferred Stock who hold, in the aggregate, more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares of Common Stock, voting together with the holders of the Preferred Stock on an as converted basis, are entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to any act or action submitted to the vote of the Company’s stockholders, except as otherwise provided by law. 2 . Description of the rights attached to the Series A Preferred Stock Holders of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value per share of the Series A Preferred Stock, which was initially $1,000 per share. Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2013, and on each conversion date (with respect to the shares of Series A Preferred Stock being converted). Until September 13, 2013, dividends were payable only in cash. Thereafter, dividends on the Series A Preferred Stock became payable, at the option of the Company, in cash and/or, if certain conditions are satisfied (including, among others, that the volume weighted average trading price for the Common Stock on its principal trading market is equal to or greater than 110% of the then current conversion price for the Series A Preferred Stock for five consecutive trading days prior to the dividend payment date), in shares of Common Stock, valued at the then current conversion price of the Series A Preferred Stock. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2016, 2015 and 2014 the Company paid an aggregate of $13,529 $57,061 and $370,441, respectively, in cash dividends to its Series A Preferred Stockholders. The Company may become obligated to redeem the Series A Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series A Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series A Preferred Stock will have the option to require the Company to redeem such holder’s shares of Series A Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder’s outstanding Series A Preferred Stock. Subject to certain conditions, the Company will have the option to force the conversion of the Series A Preferred Stock (in whole or in part) if the volume weighted average price for the Common Stock on its principal trading market exceeds $11.60 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $100,000. If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series A Preferred Stock (the “Series A Conversion Shares”) and, as a result, the holder is required by its brokerage firm to purchase shares of Common Stock to deliver in satisfaction of a sale by such holder of the Series A Conversion Shares (a “Buy-In”), the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder’s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series A Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements. In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series A Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series A Conversion Shares by the eighth trading day following the applicable conversion date. Subject to the beneficial ownership limitation described below, holders of Series A Preferred Stock will vote together with the holders of Common Stock on an as-converted basis. Holders will not be permitted to convert their Series A Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the outstanding number of shares of Common Stock outstanding after giving effect to such conversion (subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company) (the “Beneficial Ownership Limitation”). In addition, no holder may vote any shares of Series A Preferred Stock (on an as converted to Common Stock basis) in excess of the Beneficial Ownership Limitation. Subject to certain limitations, so long as any initial Series A Unit purchaser holds any shares of Series A Preferred Stock, if (1) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a Purchaser then holding Series A Preferred Stock, Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser). The conversion price of the shares of Series A Preferred Stock that were included in the Series A Units is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect ($4.50 and $5.80 per share at December 31, 2016 and 2015, respectively), as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. A. 3 . Description of the rights attached to the Series B Preferred Stock Holders of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on September 30, 2014, and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For so long as required under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock, dividends on Series B Preferred Stock will be payable only in shares of Common Stock. Thereafter, dividends on the Series B Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current conversion price of the Series B Preferred Stock or (b) the average of the volume weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2016, 2015, and 2014 the Company issued a total of 272,282, 168,926 and 18,986 shares of Common Stock, respectively at an estimated fair value of $647,215, $390,219 and $43,858, respectively as in kind dividends to holders of Series B Preferred Stock. Subject to certain ownership limitations described below, the Series B Preferred Stock is convertible at the option of the holder at any time and from time to time into shares of Common Stock at a conversion price of $5.80 per share (calculated by dividing the stated value per share of Series B Preferred Stock, which is initially $1,000, by the conversion price per share). The conversion price of the Series B Preferred Stock is subject to adjustment for certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion price then in effect, as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. In addition, the holders of Series B Preferred Stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of Common Stock to the same extent as if such holders of Series B Preferred Stock had converted all of their shares of Series B Preferred Stock prior to such distribution. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations of the Company, the holders of Series B Preferred Stock will be entitled to receive, upon conversion of their shares of Series B Preferred Stock, any securities or other consideration received by the holders of the Common Stock pursuant to the fundamental transaction. Subject to certain conditions contained in the Certificate of Designations, Preferences and Rights relating to the Series B Preferred Stock, the Company will have the option to force the conversion of the Series B Preferred Stock (in whole or in part) if (a) the volume weighted average price for the Common Stock on its principal trading market exceeds $10.00 for each of any 20 trading days during any 30 consecutive Trading Day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the Company receives approval to list the Common Stock on a national securities exchange. If the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series B Preferred Stock (the “Series B Conversion Shares”) which results in a Buy-In, the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder’s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series B Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number of shares of Series B Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements. In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series B Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series B Conversion Shares by the eighth trading day following the applicable conversion date. As long as at least 35% of the originally issued shares of Series B Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the outstanding Preferred Stock, the Company will not be permitted to, among other things, incur indebtedness or liens not permitted under the Certificate of Designations for the Series B Preferred Stock; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series B Preferred Stock; or enter into certain transactions with affiliates of the Company. Subject to any limitations under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock, the Company may become obligated to redeem the Series B Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series B Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series B Preferred Stock will have the option to require the Company to redeem such holder’s shares of Series B Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder’s outstanding Series B Preferred Stock. Subject to the Beneficial Ownership Limitation, holders of Series B Preferred Stock will vote together with the holders of Common Stock and Series A Preferred Stock on an as-converted basis. Holders will not be permitted to convert their Series B Preferred Stock if such conversion would cause such holder to beneficially own shares of outstanding Common Stock in excess of the Beneficial Ownership Limitation. Subject to certain limitations, so long as any Purchaser holds any shares of Series B Preferred Stock, if (a) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a Purchaser then holding Series B Preferred Stock, Series B Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the Purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such Purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such Purchaser). A. 4 Description of the rights attached to the Series C Preferred Stock Holders of Series C Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value per share of Series C Preferred Stock. Dividends on the Series C Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on June 30, 2016, and on each conversion date (with respect to the shares of Preferred Stock being converted). For so long as required under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock or Series B Preferred Stock, dividends will be payable only in shares of Common Stock. Thereafter, dividends on the Series C Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current conversion price of the Series C Preferred Stock or (b) the average of the volume weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the applicable dividend payment date. As of December 31, 2016, the Company issued a total of 64,148 shares of Common Stock, at an estimated fair value of $152,480, as in kind dividends to holders of Series C Preferred Stock The Series C units, each consisting of (i) one share of our newly designated Series C 5.5% Convertible Preferred Stock, par value $0.001 per share are convertible into shares of our common stock, par value $0.001 per share, at an initial conversion price of $4.50 per share, (ii) a five year warrant to purchase, at an exercise price of $4.50 per share, up to such number of shares of our common stock issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-1 Warrant”) and (iii) a five year warrant to purchase, at an exercise price of $7.75 per share, up to such number of shares of our common stock issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-2 Warrant” and, together with the Series C-1 Warrants, collectively, the “Series C Warrants”). Subject to any limitations under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock or Series B Preferred Stock, the Company may become obligated to redeem the Series C Preferred Stock in cash upon the occurrence of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series C Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series C Preferred Stock will have the option to require the Company to redeem such holder’s shares of Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder’s outstanding Series C Preferred Stock. Subject to certain conditions contained in the Certificate of Designations, Preferences and Rights relating to the Series C Preferred Stock (the “Certificate of Designations”), the Company will have the option to force the conversion of the Series C Preferred Stock (in whole or in part) if (a) the volume weighted average price for the Common Stock on its principal trading market exceeds $7.00 for each of any 20 trading days during any 30 consecutive trading day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the Company receives approval to list the Common Stock on a national securities exchange. Subject to certain exceptions contained in the Certificate of Designations, if the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series C Preferred Stock (the “Conversion Shares”) and, as a result, the holder is required by its brokerage firm to purchase shares of Common Stock to deliver in satisfaction of a sale by such holder of the Conversion Shares (a “Buy-In”), the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the shares of Series C Preferred Stock equal to the number of shares of Series C Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements. In addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series C Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Conversion Shares by the fifth trading day following the applicable conversion date and the Company will continue to pay such partial liquidated damages for each trading day after such eighth trading day until such certificates are delivered or the holder rescinds such conversion. As long as at least 35% of the originally issued shares of Series C Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the outstanding Series C Preferred Stock, the Company will not be permitted to, among other things, incur indebtedness or liens not permitted under the Certificate of Designations; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series C Preferred Stock; enter into certain transactions with affiliates of the Company; or enter into any agreement with respect to the foregoing. Subject to the beneficial ownership limitation described below, holders of Series C Preferred Stock will vote together with the holders of Common Stock, Series A Preferred Stock and Series B Preferred Stock on an as-converted basis. Holders will not be permitted to convert their Series C Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the outstanding Common Stock (subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company) (the “Beneficial Ownership Limitation”). In addition, no holder may vote any shares of Series C Preferred Stock (on an as-converted to Common Stock basis) in excess of the Beneficial Ownership Limitation. Subject to certain limitations, so long as any purchaser holds any shares of Series C Preferred Stock, if (a) the Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a purchaser then holding Series C Preferred Stock, Warrants, Conversion Shares or Warrant Shares (defined below) reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such subsequent sale of securities than are the terms and conditions granted to such purchaser after taking into account all of the terms and conditions of the terms granted to the purchasers under the purchase agreement and the terms granted in such subsequent issuance or sale, including all of the components of the Series C Units and of the securities or units involved in such subsequent issuance or sale, then the purchaser will be permitted to require the Company to amend the terms of this transaction (only with respect to such purchaser) so as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such purchaser). The Series C Warrants have a five-year term commencing on their respective issuance dates. Until the end of the applicable term, each Series C Warrant will be exercisable at any time and from time to time at an original exercise price of $4.50 per share (with respect to the Series C-1 Warrants) or $7.75 per share (with respect to the Series C-2 Warrants). The Series C Warrants contain adjustment provisions substantially similar to those to the adjustment provisions of the Series C Preferred Stock as described above, except that the Series C Warrants do not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series C Warrants. In addition, the Series C Warrants provide for protection for a Buy-In on substantially the same terms as described above with respect to the Series C Preferred Stock. No holder may exercise its Series C Warrants in excess of the Beneficial Ownership Limitation. B. The 2012 Offering On November 19, 2012, the Company issued 165,057 shares of its Common Stock at a price of $7.00 per share, for a total consideration of $1,155,399. The issuance and sale of such shares constituted the initial closing (the “Initial Closing”) of the 2012 Offering, which was originally structured as an offering of up to 785,714 shares of its Common Stock to accredited investors (the “First Closing Purchasers”) at a price of $7.00 per share in a private placement transaction. Subsequent to the Initial Closing, the 2012 Offering was converted from an offering of Common Stock to an offering of Units and, on March 13, 2013, the Company entered into a Securities Purchase Agreement with certain accredited investors (the “Series A Unit Purchasers”) pursuant to which the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units. The shares of Series A Preferred Stock comprising the Series A Units were convertible into an aggregate of 1,086,178 shares of Common Stock (based on a conversion price per share of $5.80) and the Series A Warrants comprising the Series A Units were exercisable into an aggregate of 1,086,178 shares of Common Stock at an original exercise price per share of $6.96, in each case subject to adjustment as described below. After giving effect to the payment of commissions to the Placement Agent for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $5.4 million. In connection with the 2012 Offering, the Company also agreed with the Placement Agent for the offering that, following the closing of the sale of the Series A Units, the Company would issue to the holders of the 1,295,535 shares of Common Stock issued by the Company at a price of $6.25 per share pursuant to the Company’s previously completed private placement of Common Stock (occurred during 2011 and 2010) such number of shares of Common Stock as would effectively reduce the per share purchase price paid by such holders for such shares from $6.25 per share to $5.80 per share, in each case subject to the execution by the holder of a consent to such modification. As a result, upon the receipt of executed consents to modification from all such holders, the Company has issued or will be required to issue to such holders an aggregate of additional 100,526 shares of Common Stock, of which 92,136 and 654 shares of Common Stock were issued during the years ended December 31, 2015 and 2014, respectively. C. The 2014 Offering During August until December 31, 2014, the Company raised $8.5 million in gross proceeds from the issuance of 8,500 Series B Units. After giving effect to the payment of commissions to the Placement Agent (See Note 9C) for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $7.3 million. The Series B Warrants have a five-year term commencing on the closing dates, as applicable. Until the end of their term, the Series B Warrants included in the Series B Units will be exercisable into Common Stock at any time and from time to time at an exercise price of $5.80 per share (with respect to the Series B-1 Warrants) or $10.00 per share (with respect to the Series B-2 Warrants). The Series B Warrants contain adjustment provisions substantially similar to those of the Series B Preferred Stock (See Note 10.A.3), except that the Series B Warrants shall not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series B Warrants. No holder may exercise its Series B Warrants in excess of the Beneficial Ownership Limitation. In connection with the 2014 offering the Company incurred a total of $1,787,545 of issuance costs of which $630,936 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and Note 10F.1.d). The allocation method of the issuance proceeds to the Series B Preferred Stock and to the detachable Series B Warrants and their respective issuance costs is described in Note 2T.2. Pursuant to the Securities Purchase Agreement, dated March 13, 2013, relating to the issuance by the Company of Series A Units, the Company was required to and did notify the holders of the Series A Preferred Stock of the closing of the sale of the Series B Units, and following receipt thereof such holders of Series A Preferred Stock were entitled pursuant to the “most favored nation” provision included in the Securities Purchase Agreement for the 2012 Offering, to elect to amend the terms of their purchase of Series A Units to match the terms of the Series B Units. As of December D. The 2016 Offering During the year ended December 31, 2016, the Company raised $5,828,900 in gross proceeds from the issuance of seven separate closings totaling 5,829 Series C Units. After giving effect to the payment of commissions to the Placement Agent (See Note 9C) for the offering and the payment of certain offering expenses, the Company received net proceeds from the offering of approximately $5 million. The Series C Warrants have a five-year term commencing on their respective issuance dates. Until the end of the applicable term, each Series C Warrant will be exercisable at any time and from time to time at an exercise price of $4.50 per share (with respect to the Series C-1 Warrants) or $7.75 per share (with respect to the Series C-2 Warrants). The Series C Warrants contain adjustment provisions substantially similar to those to the adjustment provisions of the Series C Preferred Stock as described above (See Note 10A.4), except that the Series C Warrants do not include dilution protection for issuances of securities at an effective price per share lower than the conversion price of such Series C Warrants. In addition, the Series C Warrants provide for protection for a Buy-In on substantially the same terms as described above with respect to the Series C Preferred Stock. No holder may exercise its Series C Warrants in excess of the Beneficial Ownership Limitation. In connection with the 2016 offering the Company incurred a total of $1,187,447 of issuance costs of which $308,238 attributable to non-cash compensation expenses relating to warrants issued to the Placement Agent (See Notes 9C and Note 10F.1.e). The allocation method of the issuance proceeds to the Series As a result of the initial issuance and sale of the Series C Units, pursuant to the terms of the Series A Warrants, on April 8, 2016 Pursuant to the purchase agreements relating to the issuance and sale of the Series A Units and the Series B Units, the Company was required to and did notify the holders of the Series A Preferred Stock and Series B Preferred Stock of the closing of the sale of the Series C Units, and following receipt thereof such holders of Series A Preferred Stock and Series B Preferred Stock will be entitled, p

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES	NOTE 11 – US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 1,510,491 1,279,216 992,991 Professional fees 58,954 71,930 83,597 Regulations related expenses 620,535 488,536 413,985 Patents 132,344 159,624 188,825 Materials 346,238 153,669 98,129 Depreciation 32,508 19,133 16,156 Travel expenses 66,211 39,324 27,867 Vehicle maintenance 91,935 54,936 25,888 Other 22,601 1,977 2,186 2,881,817 2,268,345 1,849,624

SELLING AND MARKETING EXPENSES

SELLING AND MARKETING EXPENSES	12 Months Ended
	Dec. 31, 2016
Selling, General and Administrative Expense [Abstract]
SELLING AND MARKETING EXPENSES	NOTE 12 – US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 707,111 318,716 - Professional fees 271,984 416,575 132,504 Travel & expenses 76,022 178,167 26,943 Exhibitions and Shows 72,798 175,176 49,084 Other - 38,800 22,228 1,127,915 1,127,434 230,759

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2016
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 13 – US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 938,203 584,058 548,323 Professional fees 1,046,987 573,815 749,167 Travel & expenses 130,533 114,783 173,405 Depreciation 27,076 25,759 18,527 Insurance 63,182 63,146 56,401 Vehicle maintenance 51,818 41,180 40,087 Other - - 841 2,257,799 1,402,741 1,586,751

FINANCING (INCOME) EXPENSES, NE

FINANCING (INCOME) EXPENSES, NET	12 Months Ended
	Dec. 31, 2016
Other Income and Expenses [Abstract]
FINANCING (INCOME) EXPENSES, NET	NOTE 14 – US dollars Year ended December 31, 2016 2015 2014 Israeli CPI linkage difference on principal of loans from stockholders (629 ) (2,521 ) (556 ) Exchange rate differences 27,934 38,873 (25,282 ) Change in fair value of Warrants with down-round protection (289,626 ) (149,092 ) (6,559,758 ) Interest expenses on credit from banks and other 16,216 15,205 (2,189 ) Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants - 1,284,354 - (246,105 ) 1,186,819 (6,587,785 )

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 15 – A. Measurement of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the “Inflationary Adjustment Law”) Commencing January 1, 2008, the results of operations of Integrity Israel for tax purposes are measured on a nominal basis. B. Changes in the Israeli corporate tax rates On July 30, 2013, the Israeli parliament approved the Law for the Change in National Priorities (Legislative Amendments to Achieve Budgetary Goals for 2013 and 2014) – 2013, which, among other things increased the standard Israeli corporate income tax rate from 25% to 26.5% effective as of January 1, 2014, On January 4, 2016, the Israeli parliament passed the Law for Amendment of the Income Tax Ordinance No. 216, which, among other things reduced the standard Israeli corporate income tax rate from 26.5% to 25% effective as of January 2016, Furthermore, on December 22, 2016 the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) – 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step would be to reduce the corporate tax rate to 24% as of January 2017 and the second step would be to reduce the corporate tax rate to 23% as of January 2018.This change has no impact on the financial statements. C. Tax assessments For federal, state and local income tax purposes the Company remains open for examination by the tax authorities for the tax years from 2013 through 2015 under the general statute of limitations. Notwithstanding, pursuant and subject to the provisions of article 145 of the Income Tax Ordinance, Integrity Israel’s tax returns that were filled with the tax authority up to and including 2012 are considered final. D. Carryforward tax losses As of December 31, 2016, the Company had cumulative net operating losses (NOL) for US federal purposes of approximately $4.4 million that will expire between the years 2032-2036. Integrity Israel has losses carry forward balances for Israeli income tax purposes of nearly $25.3 million to offset against future taxable income for an indefinite period of time. E. The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements: US dollars Year ended December 31, 2016 2015 2014 Pretax income (loss) (5,409,737 ) (5,842,172 ) 2,980,426 Federal tax rate 34 % 34 % 35 % Income tax expenses (benefit) computed at the ordinary tax rate (1,839,311 ) (1,986, 338 ) 1,043,149 Non-deductible expenses 34,500 31,050 27,250 Stock-based compensation 17,562 4,503 14,415 Warrants with down round protection (98,473 ) (50,691 ) (2,295,915 ) Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants - 436,680 - Tax in respect of differences in corporate tax rates 396,956 340,263 278,466 Losses and timing differences in respect of which no deferred taxes assets were recognized 1,488,766 1,224,533 932,635 - - - F. Deferred taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes. Significant components of the Group's future tax assets are as follows: US dollars December 31, 2016 2015 2014 Composition of deferred tax assets: Provision for employee-related obligation 28,526 23,494 20,220 Non-capital loss carry forwards 7,823,828 6,233,314 4,810,780 Valuation allowance (7,852,354 ) (6,256,808 ) (4,831,000 ) - - -

INCOME (LOSS) PER SHARE

INCOME (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
INCOME (LOSS) PER SHARE	NOTE 16 – The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2016, 2015 and 2014, are as follows: US dollars Year ended December 31, 2016 2015 2014 Income (loss) for the year (5,409,737 ) (5,842,172 ) 2,980,426 Cash dividend on Series A Preferred Stock (18,229 ) (57,061 ) (370,441 ) Stock dividend on Series B Preferred Stock (647,215 ) (390,219 ) (43,858 ) Stock dividend on Series C Preferred Stock (152,480 ) - - Income attributable to participating securities (Preferred Stock) - - (596,472 ) Income (loss) for the period attributable to common stockholders (6,227,661 ) (6,289,452 ) 1,969,655 Number of shares Year ended December 31, 2016 2015 2014 Common shares used in computing Basic income (loss) per share 5,788,842 5,476,870 5,304,500 Common shares used in computing Diluted income (loss) per share (*) 5,788,842 5,476, 870 5,349,242 Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**) 12,745,874 9,431,728 4,557,612 (*) In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units. (**) The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company’s Common Stock

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 17 – The Company operates in one operating segment, the following is a summary of operations within geographic areas: Year ended December 31, Revenues based on the customer’s location: 2016 2015 2014 Europe 431,772 13,420 32,000 Asia and Pacific 179,917 129,747 27,775 Total 611,689 143,167 59,775 All long-lived assets are owned by Integrity Israel and are located in Israel.

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 18 – A. Avner Gal, the beneficial owner of approximately 4.12% of the Company's outstanding Common Stock as of December 31, 2016, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Gal agreed to continue to serve as the chief executive officer and managing director of Integrity Israel. The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr. Gal’s employment agreement provides for an annual salary of approximately $125,722, $123,457 and $134,769 (NIS 480,000) for the year ended December 31, 2016, 2015 and 2014 respectively. In addition, Mr. Gal is entitled to an annual bonus to be determined by the board of directors and an additional sum provided that Mr. Gal reaches certain milestones approved by the board, as well as the payment of certain social and insurance benefits and the use of a car. During the year ended December 31, 2016, 2015 and 2014 the Company did not pay Mr. Gal any bonuses. The agreement also provides for a renegotiation of Mr. Gal’s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Gal’s bonus formula once Integrity Israel has begun commercialization of its products. The agreement is terminable by either party on 180 days’ notice, immediately by Integrity Israel with the payment of an amount equal to 180 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance. Mr. Gal is subject to a non-compete and a confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2016, the Company did not make any amendments to Mr. Gal’s employment agreement . B. David Malka, the beneficial owner of 1.64% of the Company's outstanding Common Stock as of December 31, 2016, entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Malka agreed to continue to serve as the vice president of operations of Integrity Israel. The agreement was approved by the board of directors and stockholders of Integrity Israel. Mr. Malka’s employment agreement provides for an annual salary of approximately $63,114, 61,728 and $67,302 (NIS 240,000) for the year ended December 31, 2016, 2015 and 2014 respectively. In addition, Mr. Malka is entitled to an annual bonus to be determined by the Board of Directors in its sole discretion and an additional sum provided that Mr. Malka reaches certain milestones approved by the Board, as well as the payment of certain social and insurance benefits and the use of a group three car. During the year ended December 31, 2016, 2015 and 2014 the Company did not pay Mr. Malka any bonuses. The agreement also provided for a renegotiation of Mr. Malka’s annual salary on the one-year anniversary thereof and the renegotiation of Mr. Malka’s bonus formula once Integrity Israel has begun commercialization of its products. The agreement is terminable by either party on 90 days’ notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary, or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance. Mr. Malka is subject to a non-compete and confidentiality agreement during the term of the agreement and for one year thereafter. As of December 31, 2016, the Company did not make any amendments to Mr. Malka’s employment agreement.

MAJOR CUSTOMERS AND VENDOR

MAJOR CUSTOMERS AND VENDOR	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS AND VENDOR	NOTE 19 – For the year ended December 31, 2016, sales to four customers represented approximately 90% of net sales and purchases from one vendor represented approximately 77% of net purchases.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 20 – A. On January 5, 2017, and March 8, 2017 the Company, entered into a Securities Purchase Agreement with certain accredited investors (the “Purchasers”) pursuant to which, the Company issued to the Purchasers an aggregate of 403.9 and 2,560, respectively, units of the Company’s Series C 5.5% Convertible Preferred Stock, par $0.001 per share, as described in note 10D above. The shares of Preferred Stock comprising the Units are convertible into an aggregate of 658,649 shares of Common Stock, and the Warrants comprising the Units are exercisable for an aggregate of 1,317,298 shares of Common Stock, in each case subject to certain adjustments. The Company received aggregate gross proceeds of $2,963,900 from the sale of the Units pursuant to the Purchase Agreement. Pursuant to a placement agent agreement (the “ Placement Agent Agreement ”) with the placement agent for the offering of the Units (the “ Placement Agent ”), at the closing of the sale of the Units the Company paid the Placement Agent, as a commission, an amount equal to 10% of the aggregate sales price of the Units, plus a non-accountable expense allowance equal to 3% of the aggregate sales price of the Units. In addition, pursuant to the Placement Agent Agreement, the Company is required to issue to the Placement Agent: (a) 5 year warrants to purchase up to 131,730 shares of Common Stock at an exercise price of $4.50 per share and (b) 5 year warrants to purchase up to 65,865 shares of Common Stock at an exercise price of $7.75 per share. The terms of the Placement Agent warrants will be substantially similar to the Warrants except that the Placement Agent warrants will also be exercisable on a cashless basis and will include full ratchet anti-dilution protection B. On January 31, 2017, the Board of Directors of the Company unanimously voted to appoint Sami Sassoun as the Chief Financial Officer of the Company, commencing on February 1, 2017. On February 1, 2017, the Subsidiary entered into an employment agreement (the “ Employment Agreement ”) with Mr. Sassoun to serve as Chief Financial Officer of the Company and the Subsidiary. The Employment Agreement provides for a monthly base gross salary of NIS 30,000 (approximately $8,000 based on the exchange rate of NIS 3.7461 / $1.00 USD in effect on February 1, 2017), as well as the payment of certain social benefits and the use of a company car. In addition, pursuant to the Employment Agreement, the Company has agreed to grant to Mr. Sassoun, on the one year anniversary of the commencement of his employment with the Company, options to purchase such number of shares of Common Stock of the Company, at an exercise price of $4.50 per share, with the number of options to be issued and the vesting provisions applicable thereto to be determined by the Board of Directors of the Company. The Employment Agreement is terminable by either party on 90 days’ notice or immediately by the Subsidiary for Cause (as defined in the Employment Agreement) without the payment of severance. The Employment Agreement contains non-compete obligations applicable during the term of the agreement and for one year thereafter and confidentiality obligations that survive the termination of the agreement indefinitely C. On February 6, 2017, the Company, entered into an amended and restated consulting agreement (the “ A&R Consulting Agreement Strand Strategy 2016 Effective Date Board Services The A&R Consulting Agreement contains confidentiality obligations that survive the termination of the A&R Consulting Agreement indefinitely. D. On March 20, 2017, the Company entered into an employment agreement (the “ Graham Employment Agreement ”) with Mr. Graham to serve as Chief Executive Officer of the Company. Pursuant to the terms of the Graham Employment Agreement, Mr. Graham will (1) receive a base salary of $500,000 per year; (2) be eligible to earn an annual performance bonus between 35-72% of his current base salary, subject to certain performance criteria and, provided that Mr. Graham continues to be an employee through and on March 15, 2018, Mr. Graham’s performance bonus for his first year is guaranteed up to $225,000; (3) be eligible to earn a one-time milestone bonus equal to $500,000 based upon satisfaction of the Company attaining cash on hand in the Company equal to or greater than $20,000,000 on or before December 31, 2018, provided that Mr. Graham continues to be an employee through and on the date of payment of such one-time bonus; and (4) receive certain equity awards (pursuant to the Company’s 2010 Incentive Compensation Plan, as amended) under the terms and conditions as set forth in the Graham Employment Agreement. The Graham Employment Agreement is terminable by the Company on 90 days’ prior written notice to Mr. Graham, without Cause, or immediately by the Company for Cause (as defined in the Graham Employment Agreement). The Graham Employment Agreement contains non-compete obligations applicable during the term of the agreement and for one year thereafter and confidentiality obligations that survive the termination of the agreement indefinitely.

SUMMARY OF SIGNIFICANT ACCOUN28

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of estimates in the preparation of financial statements	A. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to the consolidated financial statements, the most significant estimates and assumptions relate to (i) the fair value estimate of the Warrants with down-round protection, (ii) the
Functional currency	B. Functional currency The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel ("NIS") and its financial statements are included in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders' deficit, under “accumulated other comprehensive income (loss)”. Year ended December 31, 2016 2015 2014 Official exchange rate of NIS 1 to US dollar 0.260 0.256 0.257
Principles of consolidation	C. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
Cash and cash equivalents	D. Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents.
Inventories	E. Inventories Inventories are stated at the lower of cost or market value. Cost is determined as follows: With respect to raw materials, the Group calculates cost using the average cost method. With respect to work in process and finished products, the Group calculates the cost on the basis of the average direct manufacturing costs, including materials, labor, subcontracting costs and other direct manufacturing costs. Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, the Group has not recorded any reserves with respect to its inventory.
Property and equipment, net	F. Property and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: % Computers 33 Furniture and office equipment 7-15 Leasehold improvements Shorter of lease term
Impairment of long-lived assets	G. Impairment of long-lived assets The Group's long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses.
Long-term restricted cash	H. Long-term restricted cash Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel’s obligations in respect of its headquarters lease. See Note 9B
Income tax	I. Income tax The Group accounts for income taxes in accordance with ASC 740, "Income Taxes". Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Group’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2016, 2015 and 2014 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet.
Liability for employee rights upon retirement	J. Liability for employee rights upon retirement Integrity Israel's liability for employee rights upon retirement with respect to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees are entitled to one month's salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel makes monthly deposits to insurance policies and severance pay funds. The deposited funds may be withdrawn upon the fulfillment of Integrity Israel's severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits or losses. Commencing in 2011, Integrity Israel’s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company's balance sheet. Severance expenses for the year ended December 31, 2016, 2015 and 2014 amounted to $147,754, $111,030 and $101,220, respectively.
Revenue recognition	K. Revenue recognition Revenues are recognized in accordance with ASC 605, "Revenue Recognition" and SEC Staff Accounting Bulletin (“SAB”) No. 104, “Revenue Recognition”, when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred (See Note 2N). The Company derives its revenues from sales of its GlucoTrack® model DF-F glucose monitoring device to distributors. The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable and non-returnable and, to date, the Company has not granted to any of its distributors any rights of price protection or stock rotation. Accordingly, the Company considers its distributors as end-users for revenue recognition purposes.
Research and development expenses	L. Research and development expenses Research and development expenses are charged to operations as incurred.
Royalty-bearing grants	M. Royalty-bearing grants Royalty-bearing grants from the Office of Chief Scientist (“OCS”) to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. The cumulative research and development grants received by Integrity Israel from inception through December 2004 amounted to $93,300. Integrity Israel has not received any research and development grants since December 2004.
Warranty	N. Warranty The Group provides a 24-month warranty for its products at no cost. The Group estimates the costs that may be incurred during the warranty period and records a liability for the amounts of such costs at the time revenues are recognized. For the year ended December 31, 2016, 2015 and 2014 warranty expenses were $8,605 and, $1,157 and $0, respectively.
Basic and diluted income (loss) per share	O. Basic and diluted income (loss) per share Basic income (loss) per share is computed by dividing the income (loss) for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Preferred Stock) are considered in the computation of basic income per share using the two-class method. However, in periods of net loss, such participating securities are not included since the holders of such securities do not have a contractual obligation to share the losses of the Company. In computing, diluted income per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method” and upon the conversion of Preferred Stock using the "if-converted method", if the effect of each of such financial instruments is dilutive.
Stock-based compensation	P. Stock-based compensation The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of operations as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, "Equity-Based Payments to Non-Employees".
Fair value of financial instruments	Q. Fair value of financial instruments ASC Topic 825-10, "Financial Instruments" defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, accounts receivable, other current assets, accounts payable, current portion of long-term loans from stockholders and other current liabilities balances, to approximate their fair values due to the short-term maturities of such financial instruments. The Warrants with down-round protection represent a derivative liability and therefore are measured and presented on the balance sheet at fair value. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy. The fair value measurement of the warrants is classified as level 3. The Group did not estimate the fair value of the long-term loans from stockholders since their repayment schedule has not yet been determined.
Concentrations of credit risk	R. Concentrations of credit risk Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with major banks in Israel and the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. As of December 31, 2016, and 2015 the balances of accounts receivable was not material and accordingly such balances do not represent substantial concentration of credit risk. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Contingencies	S. Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Preferred Stock	T. Preferred Stock 1. Temporary Equity Classification As more fully described in Note 10 the Company issued Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, which provide a liquidation preference and certain redemption rights for the benefit of the holders of such Preferred Stock upon the occurrence of certain contingent events, some of which are not solely within the Company’s control. Accordingly, the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock are presented as temporary equity. 2. Initial Measurement Upon initial recognition, the Series A Preferred Stock issued together with detachable Series A Warrants (classified as a derivative liability) were measured based on the "residual approach" and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series B Preferred Stock issued together with the detachable Series B Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them. Upon initial recognition, the Series C Preferred Stock issued together with detachable Series C Warrants (classified as equity) were measured based on the relative fair value basis and were presented net of the direct issuance expenses that were allocated to them. 3. Subsequent Measurement On each balance sheet date, the Company’s management assesses the probability of redemption of the Preferred Stock (Series A, B or C). In the event that management determines such redemption to be probable as of an applicable balance sheet date, the Company will reclassify the outstanding balance of the Preferred Stock as of that date as a liability and the difference between such amount and the aggregate redemption price of the Preferred Stock will be accreted against accumulated deficit over the period beginning on the date that it becomes probable that the Preferred Stock will become redeemable and ending on the earliest redemption date. 4. Conversion Feature Analysis The Company has determined that due to the economic characteristics and risks of the Preferred Stock, based on their stated or implied substantive terms and features, Series A, Series B and Series C Preferred Stock, are considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related. As a result, the embedded conversion feature was not required to be bifurcated. Also, since at the respective issuance dates of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock, the effective exercise price of the conversion feature (based on the effective conversion rate of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock into Common Stock) was higher than the estimated fair value of the Company’s Common Stock, it was determined that the conversion feature was not beneficial. 5. Modifications or Exchanges Modifications to, or exchanges of, the Preferred Stock are accounted for as a modification or an extinguishment. Such an assessment is done by management either qualitatively or quantitatively based on the facts and circumstances of each transaction. A qualitative assessment is generally appropriate when the changes to a Preferred Stock instrument are either so inconsequential or is very significant, otherwise, a quantitative test is also applied. Since the periodic contractual cash flows of the Preferred Stock are not defined, the quantitative test is generally applied using the fair value model. Under the fair value model, the Company compares the fair value of the Preferred Stock immediately before and after the modification or exchange. If the fair values before and after the modification or exchange are substantially different, the modification or exchange is accounted for as an extinguishment, otherwise it is accounted for as a modification.
Series A Warrants with Down-Round Protection	U. Series A Warrants with Down-Round Protection The Company considered the provisions of ASC 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity”, with respect to the detachable Warrants that were issued to the Series A Unit Purchasers and to the placement agent, as described in Note 10D, and determined that as a result of the “down-round” protection that would adjust the number of Warrants and the exercise price of the Warrants based on the price at which the Company subsequently issues shares or other equity-linked financial instruments, if that price is less than the original exercise price of the Warrants, such Warrants cannot be considered as indexed to the Company's own stock. Accordingly, the Warrants were recognized as derivative liability at their fair value on initial recognition. In subsequent periods, the Warrants are marked to market with the changes in fair value recognized as financing expense or income in the consolidated statement of operations. The direct issuance expenses that were allocated to the detachable Warrants were expensed as incurred.
Recently Issued Accounting Pronouncements	V. Recently Issued Accounting Pronouncements 1. Accounting Standard Update 2014-09, “Revenue from Contracts with Customers” In May 2014, the FASB issued Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09"). ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures. During 2016, the FASB issued several Accounting Standard Updates (“ASUs”) that focus on certain implementation issues of the new revenue recognition guidance including Narrow-Scope Improvements, Practical Expedients and technical corrections. In accordance with an amendment to ASU 2014-09, introduced by Accounting Standard 2015-14, “Revenue from contracts with Customers – Deferral of the Effective Date”, for a public entity, the amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period (the first quarter of fiscal year 2018 for the Company). Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company intends to adopt ASU 2014-09 as of January 1, 2018. The Company is in the process of evaluation the impact of ASU 2014-09 on its revenue streams and selling contracts, if any, and on its financial reporting and disclosures. Management is expecting to complete the evaluation of the impact of the accounting and disclosure changes on the business processes, controls and systems throughout 2017. Since the company did not report significant revenues, management believes that the adoption of ASU 2014-09 will not have significant impact on its financial statements. 2. Accounting Standards Update 2014-15, “Presentation of Financial Statements—Going Concern” In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management’s evaluation. The amendments in ASU 2014-15 became effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Due to the current financial condition of the Company and the existing uncertainty regarding its ability to continue as a going concern, the provisions of ASU 2014-15 did not have a significant effect on the management evaluation of the Company’s ability to continue as a going concern. Certain disclosures were updated to conform to the disclosures required under ASU 2014-15. 3. Accounting Standard Update 2014-16, “Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity” Effective January 1, 2016, the Group adopted Accounting Standard Update 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity ("ASU 2014-16"). The amendments in ASU 2014-16 clarify how U.S. GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. Specifically, the amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. Furthermore, the amendments clarify that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. Rather, the nature of the host contract depends upon the economic characteristics and risks of the entire hybrid financial instrument. The amendments also clarify that, in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (i.e., the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weigh those terms and features. The assessment of the substance of the relevant terms and features should incorporate a consideration of the characteristics of the terms and features themselves; the circumstances under which the hybrid financial instrument was issued or acquired; and the potential outcomes of the hybrid financial instrument, as well as the likelihood of those potential outcomes. The amendments in ASU 2014-16 apply to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of shares. The effects of initially adopting the amendments in ASU 2014-16 were required to be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of shares as of the beginning of the fiscal year for which the amendments are effective. However, retrospective application was permitted to all relevant prior periods. Management analyzed the economic characteristics and risks of the Series A Preferred Stock and the Series B Preferred Stock (including the embedded conversion feature of each) in accordance with the provisions of ASU 2014-16 and determined that such instruments are considered as more akin to equity than debt. Accordingly, it was determined that the economic characteristics and the risks of the embedded conversion option to Common Stock and those of the Preferred Stock themselves (the 'host contract') are clearly and closely related and accordingly, the embedded conversion feature was not required to be bifurcated. As a result of the above determination, ASU 2014-16 did not impact the classification of the Series A Preferred Stock or the Series B Preferred Stock. 4. Accounting Standard Update 2015-11, “Simplifying the Measurement of Inventory” In July, 2015, The FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11"). ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) and the retail inventory method (RIM) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin). For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period. Management does not believe that the adoption of ASU 2015-11 will have significant effect on the consolidated financial statements.
Reclassifications	W. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s deficit or cash flows .

SUMMARY OF SIGNIFICANT ACCOUN29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Official Exchange Rate	Year ended December 31, 2016 2015 2014 Official exchange rate of NIS 1 to US dollar 0.260 0.256 0.257
Schedule of Property and Equipment, Rates of Depreciation	Rates of depreciation: % Computers 33 Furniture and office equipment 7-15 Leasehold improvements Shorter of lease term

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	US dollars December 31, 2016 2015 Raw materials 735,201 205,645 Work in process 633,132 551,111 Finished products 51,271 59,467 1,419,604 816,223

OTHER CURRENT ASSETS (Tables)

OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2016
Other Assets [Abstract]
Schedule of Other Current Assets	US dollars December 31, 2016 2015 Prepaid expenses 90,563 57,206 Government Institution (*) 266,431 211,586 356,994 268,792 (*) Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	US dollars December 31, 2016 2015 Computers 274,693 240,066 Furniture and office equipment 237,240 200,548 Leasehold improvements 44,686 32,898 556,619 473,512 Less – accumulated depreciation (316,167 ) (253,049 ) 240,452 220,463

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2016
Other Liabilities Disclosure [Abstract]
Schedule of Other Current Liabilities	US dollars December 31, 2016 2015 Employees and related institutions 363,738 240,358 Accrued expenses and other 349,811 187,528 713,549 427,886

COMMON STOCK, PREFERRED STOCK34

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)	12 Months Ended
	Dec. 31, 2016
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT
Schedule of Changes in Fair Value of Level 3 Liability	The changes in the fair value of the Level 3 liability are as follows (in US dollars): Warrants with Down-Round Protection December 31, 2016 2015 Balance, Beginning of the year 321,695 2,057,618 Warrants issued as consideration for placement services 308,239 - Amount classified out of stockholders’ deficit and presented as Warrants with Down-Round Protection 341,662 - Exchange of Series A Warrants pursuant to the “Most favored nation” provision (1,586,831 ) Change in fair value of Warrants with Down-Round Protection (289,626 ) (149,092 ) Balance, End of year 681,970 321,695
Schedule of Fair Value Assumptions Used	The key inputs used in the fair value calculations were as follows: December 31, December 31, Dividend yield (%) - - Expected volatility (%) (*) 56.59 105.14 Risk free interest rate (%) 0.92 0.99 Expected term of options (years) (**) 1.20 2.20 Exercise price (US dollars) 4.50 5.80 Share price (US dollars) (***) 2.38 2.31 Fair value (US dollars) 0.16 0.84 (*) Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company. (**) Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110. (***) The Common Stock price, per share reflects the Company’s management’s estimation of the fair value per share of Common Stock as of December 31, 2016, and 2015. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units at December 31, 2016, as applicable to each reporting period.
Schedule of Stock Grants Activity	The following tables present a summary of the status of the grants to employees, officers and directors as of December 31, 2016, 2015 and 2014: Number Weighted average exercise price (US$) Year ended December 31, 2016 Balance outstanding at beginning of year 413,473 6.04 Granted 149,330 4.53 Balance outstanding at end of the year 562,803 5.64 Balance exercisable at the end of the year 334,735 5.81 Number Weighted average exercise price (US$) Year ended December 31, 2015 Balance outstanding at beginning of year 450,847 5.85 Exercised (19,769 ) 1.82 Forfeited (17,605 ) 6.01 Balance outstanding at end of the year 413,473 6.04 Balance exercisable at the end of the year 293,736 5.95 Number Weighted average exercise price (US$) Year ended December 31, 2014 Balance outstanding at beginning of year 414,847 5.74 Granted 44,000 7.00 Forfeited (8,000 ) 6.25 Balance outstanding at end of the year 450,847 5.85 Balance exercisable at the end of the year 302,360 5.58
Schedule of Stock Grants, by Exercise Price Range	The following tables summarize information about options outstanding at December 31, 2016: Exercise Outstanding at December 31, 2016 Weighted average remaining contractual life (years) Exercise Exercisable at December 31, 2016 Weighted average remaining contractual life (years) 1.72 21,758 0.60 1.72 21,758 0.60 3.63 3,730 0.60 3.63 3,730 0.60 6.01 4,273 1.03 6.01 4,273 1.03 6.25 351,712 5.19 6.25 236,975 5.19 7.00 32,000 7.50 7.00 32,000 7.50 4.75 16,000 9.01 4.75 6,000 9.01 4.50 79,998 9.21 4.50 30,000 9.21 4.50 53,332 9.88 4.50 - 9.88 562,803 334,736
Schedule of Assumptions Used to Value Options	The fair value of options granted was estimated at the dates of grant using the Black-Scholes option pricing model. The following are the data and assumptions used: 2016 2015 2014 Dividend yield (%) 0 - 0 Expected volatility (%) (*) 62.16 - 105.14 Risk free interest rate (%) 1.08 - 1.61 Expected term of options (years) (**) 6 - 5-6 Exercise price (US dollars) 4.50, 4.75 - 7.00 Stock price (US dollars) (***) 2.38 - 2.31 Fair value (US dollars) 1.01, 098 - 1.59 (*) Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company. (**) Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110. (***) The Common Stock price, per share for the year ended December 31, 2014 and 2016 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2014, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2014 Offering. In reaching its estimation for December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units.

RESEARCH AND DEVELOPMENT EXPE35

RESEARCH AND DEVELOPMENT EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
Schedule of Research and Development Expenses	US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 1,510,491 1,279,216 992,991 Professional fees 58,954 71,930 83,597 Regulations related expenses 620,535 488,536 413,985 Patents 132,344 159,624 188,825 Materials 346,238 153,669 98,129 Depreciation 32,508 19,133 16,156 Travel expenses 66,211 39,324 27,867 Vehicle maintenance 91,935 54,936 25,888 Other 22,601 1,977 2,186 2,881,817 2,268,345 1,849,624

SELLING AND MARKETING EXPENSES

SELLING AND MARKETING EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
Selling, General and Administrative Expense [Abstract]
Schedule of selling and marketing expenses	US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 707,111 318,716 - Professional fees 271,984 416,575 132,504 Travel & expenses 76,022 178,167 26,943 Exhibitions and Shows 72,798 175,176 49,084 Other - 38,800 22,228 1,127,915 1,127,434 230,759

GENERAL AND ADMINISTRATIVE EX37

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2016
General And Administrative Expenses
Schedule of general and administrative expenses	US dollars Year ended December 31, 2016 2015 2014 Salaries and related expenses 938,203 584,058 548,323 Professional fees 1,046,987 573,815 749,167 Travel & expenses 130,533 114,783 173,405 Depreciation 27,076 25,759 18,527 Insurance 63,182 63,146 56,401 Vehicle maintenance 51,818 41,180 40,087 Other - - 841 2,257,799 1,402,741 1,586,751

FINANCING (INCOME) EXPENSES, 38

FINANCING (INCOME) EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2016
Other Income and Expenses [Abstract]
Schedule of Financing (Income) Expenses, Net	US dollars Year ended December 31, 2016 2015 2014 Israeli CPI linkage difference on principal of loans from stockholders (629 ) (2,521 ) (556 ) Exchange rate differences 27,934 38,873 (25,282 ) Change in fair value of Warrants with down-round protection (289,626 ) (149,092 ) (6,559,758 ) Interest expenses on credit from banks and other 16,216 15,205 (2,189 ) Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants - 1,284,354 - (246,105 ) 1,186,819 (6,587,785 )

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate	The following is a reconciliation between the theoretical tax on pre-tax income, at the tax rate applicable to the Company (federal tax rate) and the tax expense reported in the financial statements: US dollars Year ended December 31, 2016 2015 2014 Pretax income (loss) (5,409,737 ) (5,842,172 ) 2,980,426 Federal tax rate 34 % 34 % 35 % Income tax expenses (benefit) computed at the ordinary tax rate (1,839,311 ) (1,986, 338 ) 1,043,149 Non-deductible expenses 34,500 31,050 27,250 Stock-based compensation 17,562 4,503 14,415 Warrants with down round protection (98,473 ) (50,691 ) (2,295,915 ) Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants - 436,680 - Tax in respect of differences in corporate tax rates 396,956 340,263 278,466 Losses and timing differences in respect of which no deferred taxes assets were recognized 1,488,766 1,224,533 932,635 - - -
Schedule of Deferred Taxes	Significant components of the Group's future tax assets are as follows: US dollars December 31, 2016 2015 2014 Composition of deferred tax assets: Provision for employee-related obligation 28,526 23,494 20,220 Non-capital loss carry forwards 7,823,828 6,233,314 4,810,780 Valuation allowance (7,852,354 ) (6,256,808 ) (4,831,000 ) - - -

INCOME (LOSS) PER SHARE (Tables

INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Loss and Weighted Average Number of Shares	The loss and the weighted average number of shares used in computing basic and diluted loss per share for the years ended December 31, 2016, 2015 and 2014, are as follows: US dollars Year ended December 31, 2016 2015 2014 Income (loss) for the year (5,409,737 ) (5,842,172 ) 2,980,426 Cash dividend on Series A Preferred Stock (18,229 ) (57,061 ) (370,441 ) Stock dividend on Series B Preferred Stock (647,215 ) (390,219 ) (43,858 ) Stock dividend on Series C Preferred Stock (152,480 ) - - Income attributable to participating securities (Preferred Stock) - - (596,472 ) Income (loss) for the period attributable to common stockholders (6,227,661 ) (6,289,452 ) 1,969,655 Number of shares Year ended December 31, 2016 2015 2014 Common shares used in computing Basic income (loss) per share 5,788,842 5,476,870 5,304,500 Common shares used in computing Diluted income (loss) per share (*) 5,788,842 5,476, 870 5,349,242 Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share (**) 12,745,874 9,431,728 4,557,612 (*) In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units. (**) The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company’s Common Stock

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Summary of operations within geographic areas	The Company operates in one operating segment, the following is a summary of operations within geographic areas: Year ended December 31, Revenues based on the customer’s location: 2016 2015 2014 Europe 431,772 13,420 32,000 Asia and Pacific 179,917 129,747 27,775 Total 611,689 143,167 59,775

GENERAL (Details)

GENERAL (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Class of Stock [Line Items]
Accumulated deficit		$ 35,604,176			$ 29,376,515
Stockholders' deficit	$ 4,832,203	$ 10,949,430	$ 4,832,203	$ 11,063,118	$ 6,970,914
Proceeds from convertible preferred stock and warrants	$ 7,300,000			$ 5,300,000
Series B-1 Warrant [Member]
Class of Stock [Line Items]
Warrant term			5 years
Warrant exercise price	$ 5.80		$ 5.80
Series B-2 Warrant [Member]
Class of Stock [Line Items]
Warrant term			5 years
Warrant exercise price	$ 10		$ 10
Series C-2 Warrant [Member]
Class of Stock [Line Items]
Warrant term		5 years
Warrant exercise price		$ 7.75
Series C-1 Warrant [Member]
Class of Stock [Line Items]
Warrant term		5 years
Warrant exercise price		$ 4.50
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of Common Stock, net of issuance expenses		$ 4,950,000
Dividend rate		5.50%
Par value per share		$ 0.001
Conversion price		$ 4.50
Stock issued, shares		5,829
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Proceeds from issuance of Common Stock, net of issuance expenses	$ 7,300,000
Dividend rate		5.50%
Par value per share	$ 0.001		0.001
Conversion price	$ 5.80	$ 5.80	$ 5.80

SUMMARY OF SIGNIFICANT ACCOUN43

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2004USD ($)
Functional currency
Official exchange rate of NIS 1 to US dollar	0.260	0.256	0.257
Liability for employee rights upon retirement
Severance expenses	$ 147,754	$ 111,030	$ 101,220
Royalty-bearing grants
Research and development grants				$ 93,300
Warranty expenses	$ 8,605	$ 1,157	$ 0

SUMMARY OF SIGNIFICANT ACCOUN44

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property and equipment, net) (Details)	12 Months Ended
	Dec. 31, 2016
Computers [Member]
Property, Plant and Equipment [Line Items]
%	33.00%
Furniture and office equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
%	7.00%
Furniture and office equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
%	15.00%
Leasehold improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	10 years

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 735,201	$ 205,645
Work in process	633,132	551,111
Finished products	51,271	59,467
Total	$ 1,419,604	$ 816,223

OTHER CURRENT ASSETS (Details)

OTHER CURRENT ASSETS (Details) - USD ($)		Dec. 31, 2016	Dec. 31, 2015
Other Assets [Abstract]
Prepaid expenses		$ 90,563	$ 57,206
Government Institution	[1]	266,431	211,586
Total other current assets		$ 356,994	$ 268,792
[1]	Represents amounts advanced by Integrity Israel to the Israeli tax authorities or amounts owed to Integrity Israel by the Israeli Value Added Tax authorities.

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 556,619	$ 473,512
Less - accumulated depreciation	(316,167)	(253,049)
Property and equipment, net	240,452	220,463
Depreciation	59,584	44,891	$ 34,683
Purchase of property and equipment	76,455	143,736	$ 63,455
Computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	274,693	240,066
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	237,240	200,548
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 44,686	$ 32,898

OTHER CURRENT LIABILITIES (Deta

OTHER CURRENT LIABILITIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Employees and related institutions	$ 363,738	$ 240,358
Accrued expenses and other	349,811	187,528
Total other current liabilities	$ 713,549	$ 427,886

LINE OF CREDIT (Details)

LINE OF CREDIT (Details) - Dec. 31, 2016	USD ($)	ILS (₪)
Line of Credit Facility [Line Items]
Amount of unutilized credit line | $	$ 38,500
ILS [Member]
Line of Credit Facility [Line Items]
Amount of unutilized credit line | ₪		₪ 150,000

LONG-TERM LOANS FROM STOCKHOL50

LONG-TERM LOANS FROM STOCKHOLDERS (Details)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Percent of future sales to be transferred to lenders	10.00%

COMMITMENTS AND CONTINGENT LI51

COMMITMENTS AND CONTINGENT LIABILITIES (Grants) (Details)	12 Months Ended
	Dec. 31, 2004USD ($)	Dec. 31, 2004ILS (₪)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Other Commitments [Line Items]
Research and development grants	$ 93,300
ILS [Member]
Other Commitments [Line Items]
Research and development grants | ₪		₪ 420,000
Payment of Royalties to OCS [Member]
Other Commitments [Line Items]
Accrued royalties			$ 14,011	$ 8,167	$ 1,793
Royalty on the sale of any product developed, minimum	3.00%	3.00%
Royalty on the sale of any product developed, maximum	5.00%	5.00%
Contingent liabilities with respect to the grants			$ 69,330

COMMITMENTS AND CONTINGENT LI52

COMMITMENTS AND CONTINGENT LIABILITIES (Leases) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)ft²	Dec. 31, 2016ILS (₪)ft²
Property Ashkelon, Israel [Member]
Lease Disclosures:
Lease expiration date	Dec. 31, 2015
Office space leased | ft²	3,100	3,100
Monthly lease payment	$ 2,934
Property Ashkelon, Israel [Member] | ILS [Member]
Lease Disclosures:
Monthly lease payment | ₪		₪ 11,500
Property Ashdod, Israel [Member]
Lease Disclosures:
Office space leased | ft²	5,500	5,500
Monthly lease payment	$ 10,000
Lease guarantee provided to landlord	35,000
Estimated minimal rent and maintenance payments, year one	120,000
Estimated minimal rent and maintenance payments, year two	120,000
Estimated minimal rent and maintenance payments, year three	120,000
Estimated minimal rent and maintenance payments, year four	120,000
Estimated minimal rent and maintenance payments, year five	$ 120,000
Lease expiration period	5 years
Property Ashdod, Israel [Member] | ILS [Member]
Lease Disclosures:
Lease guarantee provided to landlord | ₪		₪ 137,162

COMMITMENTS AND CONTINGENT LI53

COMMITMENTS AND CONTINGENT LIABILITIES (Offering) (Details) - USD ($)	1 Months Ended	5 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2013
2014 Offering [Member] | Series B Units [Member]
Proceeds from issuance of Units		$ 8,500,000
2014 Offering [Member]
Proceeds from issuance of Units		8,500,000
Value of shares issued in offering	$ 25,000,000	$ 25,000,000			$ 25,000,000
Agreement with Placement Agent [Member]
Payments made to agent			$ 1,014,974	$ 185,000	$ 1,255,606
Monthly advisory fee owed to Placement Agent from January 2013 through December 2014						$ 12,500
Monthly advisory fee owed to Placement Agent starting January 2015				$ 20,000
2010 December Offering [Member]
Commission fee percentage					13.00%
Registration Payment Arrangement Management Fee [Member]
Commission fee percentage	4.00%				3.00%
Registration Payment Arrangement Expense Allowance [Member]
Commission fee percentage					3.00%
Registration Payment Commission Rate [Member]
Commission fee percentage	6.00%

COMMITMENTS AND CONTINGENT LI54

COMMITMENTS AND CONTINGENT LIABILITIES (Litigation) (Details)	1 Months Ended		12 Months Ended
	Feb. 28, 2016USD ($)	Mar. 31, 2015USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Apr. 30, 2016shares	Apr. 30, 2015USD ($)	Apr. 30, 2015ILS (₪)	Mar. 23, 2015USD ($)	Mar. 23, 2015ILS (₪)	Mar. 18, 2015shares
Loss Contingencies [Line Items]
Warrants issued			$ 681,970	$ 321,695
Incremental fair market value adjustments of warrants			(289,626)	$ (149,092)	$ (6,559,758)
Arbitration Ruling [Member]
Loss Contingencies [Line Items]
Number of shares of the Company's outstanding Common Stock transferred | shares											440,652
Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement									$ 439,939
Exchange rate							1	1
Partial reimbursement of attorney's fees required to pay							$ 81,870
Arbitration Ruling [Member] | ILS [Member]
Loss Contingencies [Line Items]
Amount paid as repayment in full of the outstanding principal amount under the Investment Agreement | ₪										₪ 1,767,674
Exchange rate							3.861	3.861	4.018	4.018
Partial reimbursement of attorney's fees required to pay | ₪								₪ 316,100
Advisory Agreement with AGI [Member]
Loss Contingencies [Line Items]
Warrants issued	$ 422,077
Warrants issued, number | shares		439,674				439,674
Warrant expiration date	Dec. 31, 2019
Incremental fair market value adjustments of warrants		$ 341,662	$ 211,077

COMMON STOCK, PREFERRED STOCK55

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Description of Rights Attached to Stock) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Series C-2 Warrant [Member]
Temporary Equity [Line Items]
Warrants term	5 years
Warrant exercisable price per share	$ 7.75
Series C-1 Warrant [Member]
Temporary Equity [Line Items]
Warrants term	5 years
Warrant exercisable price per share	$ 4.50
Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Dividend rate, percentages	5.50%
Convertible preferred stock, stated value for determining liquidated damages	$ 1,000
Dividend late fee rate	9.00%
Stock dividend on Preferred Stock, shares	64,148
Stock dividend on Preferred Stock, value	$ 152,480
Volume weighted average trading price for forced conversion of Preferred Stock	7
Average daily dollar trading value for forced conversion of Preferred Stock	$ 50,000
Preferred stock, liquidating damages	$ 10
Convertible preferred stock, percentage outstanding which requires written consent of shareholders for Company to enter into certain transactions	35.00%
Convertible preferred stock, maximum beneficial ownership of Common Stock permitted to owners	4.99%
Convertible preferred stock, maximum beneficial ownership of Common Stock permitted to owners, after notice given to Company	9.99%
Conversion price	$ 4.50
Convertible Preferred Stock, par value per share	$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Dividend rate, percentages	5.50%
Convertible preferred stock, stated value for determining liquidated damages	$ 1,000
Dividend requirement threshold	110.00%
Dividend late fee rate	9.00%
Preferred dividends paid	$ 13,529	$ 57,061	$ 370,441
Volume weighted average trading price for forced conversion of Preferred Stock	11.60
Average daily dollar trading value for forced conversion of Preferred Stock	$ 100,000
Preferred stock, liquidating damages	$ 10
Convertible preferred stock, percentage outstanding which requires written consent of shareholders for Company to enter into certain transactions	15.00%
Convertible preferred stock, maximum beneficial ownership of Common Stock permitted to owners	4.99%
Convertible preferred stock, maximum beneficial ownership of Common Stock permitted to owners, after notice given to Company	9.99%
Conversion price	$ 4.50
Series B Preferred Stock [Member]
Temporary Equity [Line Items]
Dividend rate, percentages	5.50%
Convertible preferred stock, stated value for determining liquidated damages	$ 1,000
Dividend late fee rate	9.00%
Stock dividend on Preferred Stock, shares	272,282	168,926	18,986
Stock dividend on Preferred Stock, value	$ 647,215	$ 390,219	$ 43,858
Volume weighted average trading price for forced conversion of Preferred Stock	10
Average daily dollar trading value for forced conversion of Preferred Stock	$ 50,000
Preferred stock, liquidating damages	$ 10
Convertible preferred stock, percentage outstanding which requires written consent of shareholders for Company to enter into certain transactions	35.00%
Conversion price	$ 5.80		$ 5.80

COMMON STOCK, PREFERRED STOCK56

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Offering) (Details) - USD ($)	May 14, 2013	May 13, 2013	Mar. 13, 2013	Nov. 19, 2012	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 08, 2016
Temporary Equity [Line Items]
Proceeds from convertible preferred stock and warrants					$ 7,300,000				$ 5,300,000
Stock price at which stock dividend is declared					$ 5.80			$ 5.80
Stock dividend
Non-cash compensation expense						$ 308,239		$ 630,936
Non-cash charge recorded to finance expense as result of warrant exchange							$ 1,284,354
Warrant [Member]
Temporary Equity [Line Items]
Number of warrants exchanged							1,440,880
Series B-1 Warrant [Member]
Temporary Equity [Line Items]
Warrants term								5 years
Warrant exercise price					5.80			$ 5.80
Number of warrants exchanged							1,200,710
Series B-2 Warrant [Member]
Temporary Equity [Line Items]
Warrants term								5 years
Warrant exercise price					$ 10			$ 10
Number of warrants exchanged							1,200,710
Warrants Issued under Securities Purchase Agreement [Member]
Temporary Equity [Line Items]
Number of shares covered by warrants					1,086,178			1,086,178
Warrant exercise price					$ 6.96			$ 6.96
Scenario, Plan [Member]
Temporary Equity [Line Items]
Stock issued, shares	2,824,471
Shares convertible into	1,284,925
Number of shares covered by warrants	1,539,546
Common Stock [Member]
Temporary Equity [Line Items]
Stock dividend								$ 1
Series C-1 Warrant [Member]
Temporary Equity [Line Items]
Warrants term						5 years
Warrant exercise price						$ 4.50
Series C-2 Warrant [Member]
Temporary Equity [Line Items]
Warrants term						5 years
Warrant exercise price						$ 7.75
Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Stock issued, shares						5,829
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares							6,931
Series B Preferred Stock [Member]
Temporary Equity [Line Items]
Number of Series A Preferred Stock shares exchanged for Series B Preferred Stock shares							6,931
2016 Offering [Member]
Temporary Equity [Line Items]
Number of shares covered by warrants						259,068
Warrants term						5 years
2016 Offering [Member] | Series C-1 Warrant [Member]
Temporary Equity [Line Items]
Warrant exercise price						$ 4.50
2016 Offering [Member] | Series C-2 Warrant [Member]
Temporary Equity [Line Items]
Warrant exercise price						$ 7.75
2016 Offering [Member] | Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Net proceeds from issuance of Units						$ 5,000,000
Gross proceeds from issuance of Units						$ 5,858,900
Number of units sold						5,829
Warrants term						5 years
Total issuance costs						$ 1,187,447
Non-cash compensation expense						$ 308,238
2016 Offering [Member] | Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Warrant exercise price											$ 4.50
Conversion price per share of preferred stock											4.50
2016 Offering [Member] | Series B Preferred Stock [Member]
Temporary Equity [Line Items]
Conversion price per share of preferred stock											$ 4.50
2012 Offering [Member]
Temporary Equity [Line Items]
Stock issued, shares				165,057
Common stock issued, price per share				$ 7
Amount of issuance				$ 1,155,399
Number of shares offered				785,714
Number of units sold			6,300
Proceeds from convertible preferred stock and warrants								$ 5,400,000
Total issuance costs										$ 1,479,864
Non-cash compensation expense										$ 562,805
2012 Offering [Member] | Scenario, Plan [Member]
Temporary Equity [Line Items]
Stock issued, shares		1,295,535
2012 Offering [Member] | Common Stock [Member]
Temporary Equity [Line Items]
Stock issued, shares							92,136	654
Stock dividend, shares								100,526
2012 Offering [Member] | Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred stock conversion price			$ 5.80
Shares convertible into			1,086,178
2014 Offering [Member]
Temporary Equity [Line Items]
Gross proceeds from issuance of Units					$ 8,500,000
Number of units sold					8,500
Warrants term					5 years			5 years
Proceeds from convertible preferred stock and warrants					$ 7,300,000
Total issuance costs								$ 1,787,545
Non-cash compensation expense								$ 630,936

COMMON STOCK, PREFERRED STOCK57

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Warrants with down round protection) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Aug. 29, 2014
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants exchanged		1,440,880
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants term	5 years
Warrant exercise price	$ 6.96			$ 5.80
Number of warrants exercisable	491,006	380,953	1,539,364
Series B-1 Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants term			5 years
Warrant exercise price			$ 5.80
Number of warrants exchanged		1,200,710
Series B-2 Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants term			5 years
Warrant exercise price			$ 10
Number of warrants exchanged		1,200,710

COMMON STOCK, PREFERRED STOCK58

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Changes in Fair Value of Level 3 Liability) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' DEFICIT
Balance, Beginning of the year	$ 321,695	$ 2,057,618
Warrants issued as consideration for placement services	308,239		$ 630,936
Amount classified out of stockholders' deficit and presented as Warrants with Down-Round Protection	341,662
Exchange of Series A Warrants pursuant to the “Most favored nation” provision		(1,586,831)
Change in fair value of Warrants with Down-Round Protection	(289,626)	(149,092)
Balance, End of year	$ 681,970	$ 321,695	$ 2,057,618

COMMON STOCK, PREFERRED STOCK59

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Warrant Inputs) (Details) - $ / shares		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Common Stock [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Share price	[1]	$ 2.38	$ 2.31
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield
Expected volatility	[2]	56.59%	105.14%
Risk free interest rate		0.92%	0.99%
Expected term of options	[3]	1 year 2 months 12 days	2 years 2 months 12 days
Exercise price		$ 4.50	$ 5.80
Fair value		$ 0.16	$ 0.84
[1]	The Common Stock price, per share reflects the Company's management's estimation of the fair value per share of Common Stock as of December 31, 2016, and 2015. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units at December 31, 2016, as applicable to each reporting period.
[2]	Due to the low trading volume of the Company's Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.
[3]	Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.

COMMON STOCK, PREFERRED STOCK60

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Non-Employees) (Details) - USD ($)

5 Months Ended

12 Months Ended

Dec. 31, 2014

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2008

Dec. 31, 2006

Dec. 31, 2005

Apr. 08, 2016

Aug. 29, 2014

Sep. 30, 2013

Mar. 13, 2013

Share-based Goods and Nonemployee Services Transaction [Line Items]

Common Stock, par value per share

$ 0.001

$ 0.001

Non-cash compensation expense

$ 308,239

$ 630,936

Amount classified out of stockholders deficit and presented as Warrants with Down-Round Protection within long-term liabilities

$ 341,662

$ 400,671

Regulatory Services [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

21,640

Exercise price

$ 0.001

Investor Finders [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

8,989

45,531

Exercise price

$ 5.517

$ 4.305

Options forfeited

5,365

17,657

Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

45,097

84,459

Warrant exercise price

$ 6.25

$ 6.25

Warrants Issued to Placement Agent, Tranche One [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Warrant exercise price

$ 6.96

Warrants Issued to Placement Agent, Tranche Two [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Warrant exercise price

$ 5.80

2012 Offering [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Non-cash compensation expense

$ 562,805

Share price

$ 2.77

2012 Offering [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

42,549

Exercise price

$ 7.75

Number of shares covered by warrants

364,071

282,469

Warrants term

2 years 3 months 22 days

Warrant exercise price

$ 4.50

$ 5.80

$ 5.80

Fair value

$ 0.16

$ 0.84

$ 1.13

Assumed dividend yield

0.00%

0.00%

0.00%

Expected volatility

56.59%

105.14%

105.14%

Assumed risk free interest rate

0.92%

0.99%

1.14%

Expected term

1 year 2 months 12 days

2 years 2 months 12 days

Assumed exercise price

$ 4.50

$ 5.80

Share price

$ 2.38

$ 2.31

2012 Offering [Member] | Minimum [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Warrant exercise price

$ 4.50

2012 Offering [Member] | Maximum [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of shares covered by warrants

179,939

Warrant exercise price

$ 5.80

2012 Offering [Member] | Exercise Price $5.80 [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

128,277

Warrants term

5 years

Warrant exercise price

$ 5.80

2012 Offering [Member] | Exercies Price $6.96 [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

128,277

Warrants term

5 years

Warrant exercise price

$ 6.96

2012 Offering [Member] | Exercise Price $7.00 [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

215

Warrants term

5 years

Warrant exercise price

$ 7

2010 Offering [Member] | Placement Agent [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of shares covered by warrants

139,608

Warrant exercise price

$ 5.80

2014 Offering [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Non-cash compensation expense

$ 630,936

Warrants term

5 years

5 years

Fair value

$ 1.40

Assumed dividend yield

0.00%

Expected volatility

105.14%

Assumed risk free interest rate

1.66%

Share price

$ 2.31

$ 2.31

2014 Offering [Member] | Minimum [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Assumed exercise price

5.8

5.8

2014 Offering [Member] | Maximum [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Assumed exercise price

10

$ 10

2014 Offering [Member] | Exercise Price $5.80 [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

293,115

Warrants term

5 years

Warrant exercise price

5.80

$ 5.80

2014 Offering [Member] | Exercise Price $10.00 [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of securities issued

146,559

Warrant exercise price

$ 10

$ 10

2014 Offering [Member] | Exercise Price $4.50 [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Warrant exercise price

4.50

2014 Offering [Member] | Exercise Price $7.75 [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Warrant exercise price

$ 7.75

2016 Offering [Member]

Share-based Goods and Nonemployee Services Transaction [Line Items]

Number of shares covered by warrants

259,068

Warrants term

5 years

Fair value

$ 0.79

Assumed dividend yield

0.00%

Expected volatility

62.16%

Assumed risk free interest rate

1.21%

Assumed exercise price

$ 7.75

Share price

$ 2.38

COMMON STOCK, PREFERRED STOCK61

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Grants to Employees Narrative) (Details) - USD ($)		Nov. 15, 2016	Mar. 17, 2016	Jan. 02, 2016	Mar. 12, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2007
Options Issued to Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period						149,330		44,000
Share price	[1]					$ 2.38		$ 2.31
Options Issued to Employees [Member] | Two Other Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period		26,666
Exercise price		$ 4.50
Vesting rights description						Each director’s option grant will vest in eight equal quarterly increments of 3,333.25 each (subject to the director’s continued service as of each such date) commencing on February 15, 2017.
Options Issued to Employees [Member] | Three Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period			26,666
Exercise price			$ 4.50
Vesting rights description						Each director’s option grant will vest in eight equal quarterly increments of 3,333.25 each (subject to the director’s continued service as of each such date) commencing with the second quarter of 2016.
Options Issued to Employees [Member] | Chief Operations Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period				16,000
Exercise price				$ 4.75
Vesting rights description						The Options will vest in eight equal quarterly installments, with the first such installment to vest on June 30, 2016.
Options Issued to Employees [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period					264,778
Exercise price					$ 6.25
Options Issued to Employees [Member] | Executive Vice President [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period					79,434
Exercise price					$ 6.25
Options Issued to Employees [Member] | Grants To Messrs Gal And Malka [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs expected to be recognized during the years ending December 31, 2015						$ 353,000
Unrecognized compensation costs expected to be recognized during the years ending December 31, 2016						$ 81,900
Integrity Israel Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum contractual term									10 years
2010 Share Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock reserved for issuance			1,000,000				529,555
Shares available for future grants						437,197
Aggregate intrinsic value of the awards exercisable						$ 14,368	$ 12,845	$ 23,830
Aggregate intrinsic value of the awards outstanding						$ 14,368	$ 12,845	$ 23,830
[1]	The Common Stock price, per share reflects the Company's management's estimation of the fair value per share of Common Stock as of December 31, 2016, and 2015. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units at December 31, 2016, as applicable to each reporting period.

COMMON STOCK, PREFERRED STOCK62

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Status of Grants to Employees) (Details) - Options Issued to Employees [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number
Balance outstanding at beginning of period	413,473	450,847	414,847
Granted	149,330		44,000
Exercised		(19,769)
Forfeited		(17,605)	(8,000)
Balance outstanding at end of the period	562,803	413,473	450,847
Balance exercisable at the end of the period	334,735	293,736	302,360
Weighted average exercise price (US$)
Balance outstanding at beginning of period	$ 6.04	$ 5.85	$ 5.74
Granted	4.53		7
Exercised		1.82
Forfeited		6.01	6.25
Balance outstanding at end of the period	5.64	6.04	5.85
Balance exercisable at the end of the period	$ 5.81	$ 5.95	$ 5.85

COMMON STOCK, PREFERRED STOCK63

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Information about Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding at December 31 | shares	562,803
Exercisable at December 31 | shares	334,736
$1.72 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 1.72
Maximum exercise price	$ 1.72
Outstanding at December 31 | shares	21,758
Weighted average remaining contractual life years	7 months 6 days
Weighted average exercise price	$ 1.72
Exercisable at December 31 | shares	21,758
Weighted average remaining contractual life years	7 months 6 days
$3.63 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 3.63
Maximum exercise price	$ 3.63
Outstanding at December 31 | shares	3,730
Weighted average remaining contractual life years	7 months 6 days
Weighted average exercise price	$ 3.63
Exercisable at December 31 | shares	3,730
Weighted average remaining contractual life years	7 months 6 days
$6.01 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 6.01
Maximum exercise price	$ 6.01
Outstanding at December 31 | shares	4,273
Weighted average remaining contractual life years	1 year 11 days
Weighted average exercise price	$ 6.03
Exercisable at December 31 | shares	4,273
Weighted average remaining contractual life years	1 year 11 days
$6.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 6.25
Maximum exercise price	$ 6.25
Outstanding at December 31 | shares	351,712
Weighted average remaining contractual life years	5 years 2 months 9 days
Weighted average exercise price	$ 6.25
Exercisable at December 31 | shares	236,975
Weighted average remaining contractual life years	5 years 2 months 9 days
$7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 7
Maximum exercise price	$ 7
Outstanding at December 31 | shares	32,000
Weighted average remaining contractual life years	7 years 6 months
Weighted average exercise price	$ 7
Exercisable at December 31 | shares	32,000
Weighted average remaining contractual life years	7 years 6 months
$4.75 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 4.75
Maximum exercise price	$ 4.75
Outstanding at December 31 | shares	16,000
Weighted average remaining contractual life years	9 years 4 days
Weighted average exercise price	$ 4.75
Exercisable at December 31 | shares	6,000
Weighted average remaining contractual life years	9 years 4 days
$4.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 4.50
Maximum exercise price	$ 4.50
Outstanding at December 31 | shares	79,998
Weighted average remaining contractual life years	9 years 2 months 16 days
Weighted average exercise price	$ 4.50
Exercisable at December 31 | shares	30,000
Weighted average remaining contractual life years	9 years 2 months 16 days
$4.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Minimum exercise price	$ 4.50
Maximum exercise price	$ 4.50
Outstanding at December 31 | shares	53,332
Weighted average remaining contractual life years	9 years 10 months 17 days
Weighted average exercise price	$ 4.50
Exercisable at December 31 | shares
Weighted average remaining contractual life years	9 years 10 months 17 days

COMMON STOCK, PREFERRED STOCK64

COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Schedule of Assumptions Used to Value Options) (Details) - Options Issued to Employees [Member] - $ / shares		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
The following are the data and assumptions used:
Dividend yield		0.00%		0.00%
Expected volatility	[1]	62.16%		105.14%
Risk free interest rate		1.08%		1.61%
Expected term of options	[2]	6 years
Exercise price				$ 7
Share price	[3]	$ 2.38		2.31
Fair value		101,098		$ 1.59
Minimum [Member]
The following are the data and assumptions used:
Expected term of options	[2]			5 years
Exercise price		4.50
Maximum [Member]
The following are the data and assumptions used:
Expected term of options	[2]			6 years
Exercise price		$ 4.75
[1]	Due to the low trading volume of the Company's Common Stock, the expected volatility was based on the historical volatility of the share price of other public companies that operate in the same industry sector as the Company.
[2]	Due to the fact that the Company does not have sufficient historical exercise data, the expected term was determined based on the "simplified method" in accordance with Staff Accounting Bulletin No. 110.
[3]	The Common Stock price, per share reflects the Company's management's estimation of the fair value per share of Common Stock as of December 31, 2016, and 2015. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units at December 31, 2016, as applicable to each reporting period.

RESEARCH AND DEVELOPMENT EXPE65

RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total research and development expenses, net	$ 2,881,817	$ 2,268,345	$ 1,849,624
Research and Development Expense [Member]
Salaries and related expenses	1,510,491	1,279,216	992,991
Professional fees	58,954	71,930	83,597
Regulations related expenses	620,535	488,536	413,985
Patents	132,344	159,624	188,825
Materials	346,238	153,669	98,129
Depreciation	32,508	19,133	16,156
Travel expenses	66,211	39,324	27,867
Vehicle maintenance	91,935	54,936	25,888
Other	22,601	1,977	2,186
Total research and development expenses, net	$ 2,881,817	$ 2,268,345	$ 1,849,624

SELLING AND MARKETING EXPENSE66

SELLING AND MARKETING EXPENSES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total selling and marketing expenses	$ 1,127,915	$ 1,127,434	$ 230,759
Selling and Marketing Expense [Member]
Salaries and related expenses	707,111	318,716
Professional fees	271,984	416,575	132,504
Travel & expenses	76,022	178,167	26,943
Exhibitions and Shows	72,798	175,176	49,084
Other		38,800	22,228
Total selling and marketing expenses	$ 1,127,915	$ 1,127,434	$ 230,759

GENERAL AND ADMINISTRATIVE EX67

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total general and administrative expenses	$ 2,257,799	$ 1,402,741	$ 1,586,751
General and Administrative Expense [Member]
Salaries and related expenses	938,203	584,058	548,323
Professional fees	1,046,987	573,815	749,167
Travel & expenses	130,533	114,783	173,405
Depreciation	27,076	25,759	18,527
Insurance	63,182	63,146	56,401
Vehicle maintenance	51,818	41,180	40,087
Other			841
Total general and administrative expenses	$ 2,257,799	$ 1,402,741	$ 1,586,751

FINANCING (INCOME) EXPENSES, 68

FINANCING (INCOME) EXPENSES, NET (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Income and Expenses [Abstract]
Israeli CPI linkage difference on principal of loans from stockholders	$ (629)	$ (2,521)	$ (556)
Exchange rate differences	27,934	38,873	(25,282)
Change in fair value of Warrants with down-round protection	(289,626)	(149,092)	(6,559,758)
Interest expenses on credit from banks and other	16,216	15,205	(2,189)
Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants		1,284,354
Financing expenses, net	$ (246,105)	$ 1,186,819	$ (6,587,785)

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016USD ($)
Parent Company [Member] | U.S. Federal [Member]
Operating Loss Carryforwards [Line Items]
Loss carry forward balances	$ 4.4
Parent Company [Member] | U.S. Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date	Dec. 31, 2032
Parent Company [Member] | U.S. Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date	Dec. 31, 2036
Ad Integrity Applications Ltd [Member] | Israel [Member]
Operating Loss Carryforwards [Line Items]
Loss carry forward balances	$ 25.3

INCOME TAX (Reconciliation of S

INCOME TAX (Reconciliation of Statutory Tax Rate to the Effective Income Tax Rate) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Pretax income (loss)	$ (5,409,737)	$ (5,842,172)	$ 2,980,426
Federal tax rate	34.00%	34.00%	35.00%
Income tax expenses (benefit) computed at the ordinary tax rate	$ (1,839,311)	$ (1,986,338)	$ 1,043,149
Non-deductible expenses	34,500	31,050	27,250
Stock-based compensation	17,562	4,503	14,415
Warrants with down round protection	(98,473)	(50,691)	(2,295,915)
Loss on partial extinguishment of Series A Preferred Stock and Series A Warrants		436,680
Tax in respect of differences in corporate tax rates	396,956	340,263	278,466
Losses and timing differences in respect of which no deferred taxes assets were recognized	1,488,766	1,224,533	932,635
Tax expense reported in the financial statements

INCOME TAX (Deferred Taxes) (De

INCOME TAX (Deferred Taxes) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Composition of deferred tax assets:
Provision for employee-related obligation	$ 28,526	$ 23,494	$ 20,220
Non-capital loss carry forwards	7,823,828	6,233,314	4,810,780
Valuation allowance	(7,852,354)	(6,256,808)	(4,831,000)
Total deferred taxes

INCOME (LOSS) PER SHARE (Detail

INCOME (LOSS) PER SHARE (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income (loss) for the year		$ (5,409,737)	$ (5,842,172)	$ 2,980,426
Income attributable to participating securities (Preferred Stock)				(596,472)
Income (loss) for the period attributable to common stockholders		$ (6,227,661)	$ (6,289,452)	$ 1,969,655
Number of shares:
Common shares used in computing Basic income (loss) per share		5,788,842	5,476,870	5,304,500
Common shares used in computing Diluted income (loss) per share	[1]	5,788,842	5,476,870	5,349,242
Total weighted average number of Common shares related to outstanding convertible Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share	[2]	12,745,874	9,431,728	4,557,612
Series A Preferred Stock [Member]
Dividend on Preferred Stock		$ (18,229)	$ (57,061)	$ (370,441)
Series B Preferred Stock [Member]
Dividend on Preferred Stock		(647,215)	(390,219)	(43,858)
Series C Preferred Stock [Member]
Dividend on Preferred Stock		$ (152,480)
[1]	In applying the treasury method, the average market price of Common Stock was based on management estimate. For December 31, 2016, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units. For December 31, 2015 and 2014, management estimation considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series B Units (See Note 10C).
[2]	The Company excludes from the calculation of diluted income (loss) per share, shares that will be issued upon the exercise of options and warrants with exercise prices, that are greater than the estimated average market value of the Company's Common Stock and shares issuable upon conversion of Preferred Stock because their effect would be anti-dilutive. Outstanding shares that will be issued upon conversion or exercise, as applicable, of all convertible Preferred Stock, stock options and warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive.

SEGMENT INFORMATION (Revenues b

SEGMENT INFORMATION (Revenues based on the customer's location) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)item	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 611,689	$ 143,167	$ 59,775
Number of operating segment | item	1
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 431,772	13,420	32,000
Asia and Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 179,917	$ 129,747	$ 27,775

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Avner Gal [Member]
Related Party Transaction [Line Items]
Ownership percentage	4.12%
Amount of related party transaction relating to annual salary	$ 125,722	$ 123,457	$ 134,769
Bonuses paid to related party
Avner Gal [Member] | ILS [Member]
Related Party Transaction [Line Items]
Amount of related party transaction relating to annual salary			480,000
David Malka [Member]
Related Party Transaction [Line Items]
Ownership percentage	1.64%
Amount of related party transaction relating to annual salary	$ 63,114	61,728	67,302
Bonuses paid to related party
David Malka [Member] | ILS [Member]
Related Party Transaction [Line Items]
Amount of related party transaction relating to annual salary			$ 240,000

MAJOR CUSTOMERS AND VENDOR (Det

MAJOR CUSTOMERS AND VENDOR (Details)	12 Months Ended
	Dec. 31, 2016
Net Sales [Member] | Sales to Four Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	90.00%
Purchases [Member] | Purchases From One Vendor [Member]
Concentration Risk [Line Items]
Concentration risk percentage	77.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	Mar. 08, 2017USD ($)$ / sharesshares	Jan. 05, 2017$ / sharesshares	Jan. 05, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)	Jan. 31, 2017USD ($)$ / shares	Jan. 31, 2017ILS (₪)	Dec. 31, 2014USD ($)	Dec. 31, 2016$ / sharesshares	Dec. 31, 2013USD ($)	Feb. 06, 2017USD ($)$ / sharesshares	Dec. 31, 2015$ / sharesshares
Subsequent Event [Line Items]
Proceeds from convertible preferred stock and warrants | $							$ 7,300,000		$ 5,300,000
Common stock par value								$ 0.001			$ 0.001
Common stock shares issued | shares								6,026,527			5,690,097
Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Dividend rate								5.50%
Par value per share								$ 0.001
Conversion price								$ 4.50
Stock issued, shares | shares								5,829
Series C-2 Warrant [Member]
Subsequent Event [Line Items]
Warrant term								5 years
Warrant exercise price								$ 7.75
Placement Agent Agreement One [Member]
Subsequent Event [Line Items]
Warrant term								5 years
Warrant exercise price								$ 7.75
Number of shares covered by warrants | shares								65,865
Placement Agent Agreement [Member]
Subsequent Event [Line Items]
Commission as a percentage of aggregate sales price								10.00%
Non-accountable expense allowance percenatge								3.00%
Warrant term								5 years
Warrant exercise price								$ 4.50
Number of shares covered by warrants | shares								131,730
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Proceeds from convertible preferred stock and warrants | $	$ 2,963,900		$ 2,963,900
Preferred stock issued | shares	2,560	4,039	4,039
Warrants Units exercisable for an common stock | shares	1,317,298		1,317,298
Shares convertible into | shares	658,649		658,649
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Dividend rate	5.50%	5.50%
Par value per share	$ 0.001	$ 0.001	$ 0.001
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Series C-2 Warrant [Member]
Subsequent Event [Line Items]
Warrant term	5 years	5 years
Subsequent Event [Member] | Chief Executive Officer [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Base gross salary with certain social benefits | $				$ 500,000
Guaranteed performance bonus for first year of service | $				225,000
One time milestone bonus amount that can be earned | $				$ 500,000
Subsequent Event [Member] | Chief Executive Officer [Member] | Employment Agreement [Member] | Minimum [Member]
Subsequent Event [Line Items]
Annual performance bonus stated as percentage of current base salary				35.00%
Subsequent Event [Member] | Chief Executive Officer [Member] | Employment Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Annual performance bonus stated as percentage of current base salary				72.00%
Subsequent Event [Member] | Directors [Member] | Employment Agreement [Member]
Subsequent Event [Line Items]
Exchange rate					3.7461
Base gross salary with certain social benefits | $					$ 8,000
Warrant exercise price					$ 4.50
Subsequent Event [Member] | Directors [Member] | Employment Agreement [Member] | ILS [Member]
Subsequent Event [Line Items]
Base gross salary with certain social benefits | ₪						₪ 30,000
Subsequent Event [Member] | Directors [Member] | A&R Consulting Agreement [Member]
Subsequent Event [Line Items]
Common stock par value										$ 0.001
Common stock shares issued | shares										10,000
Fee paid | $										$ 60,000
Strand strategy fee paid in cash percenatge										25.00%
Strand strategy fee paid paid by the grant										75.00%